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ABSTRACT
EXTRACELLULAR VESICLES FROM LACTOBACILLUS RHAMNOSUS GG
PROTECT AGAINST ALCOHOL-INDUCED LIVER INJURY THROUGH
SUPPRESSION OF INTESTINAL MIR194 AND SUBSEQUENT ACTIVATION
OF FXR IN MICE
Mengwei Jiang
Jan 24, 2022
Numerous studies have reported the efficacy of probiotics for alcohol-associated
liver disease (ALD). These studies indicate a strong interest among the scientific
and medical communities in identifying alternative or adjunctive approaches for
ALD, for which there is no effective or widely accepted therapeutic option.
However, in-depth molecular knowledge on how probiotics render their effects is
lacking. Patients with ALD often have increased hepatic bile acids (BAs), which
can be toxic and are an important causative factor in liver injury and hepatocyte
death. BAs are released into the intestines and serve not only as a “detergent” to
promote fat absorption, but also as signal molecules to regulate biological
functions through modulation of several receptors, including farnesoid X receptor
(FXR). Intestinal FXR activation upregulates fibroblast growth factor (FGF) 15/19
(mouse/human), which is released from the intestine and binds to its receptors,
FGFR/β-klotho, in the liver, and activates multiple signaling cascades to
suppress BA synthesis and reduce lipogenesis. Activation of intestinal FXR
improved ALD in animal models. While FXR activation by BAs is well-studied, its
regulation at the transcription level is less clear.
The present study demonstrated that microRNA (miR)194 levels were increased
in the feces of patients with ALD and in the feces and intestine tissues of mice
v

fed alcohol. miR194 suppressed FXR expression in intestine tissues, ileal
organoids, and intestinal epithelial cells. Decreased FXR expression caused by
the increased miR194 in the intestine led to a reduction of FGF15 expression and
subsequent increased hepatic BA synthesis and lipogenesis in alcohol-fed mice.
We further demonstrated that the alcohol increased-miR194 expression was
mediated by gut microbiota regulation of taurine metabolism through taurine
upregulated gene 1 (Tug1). Importantly, administration of Lactobacillus
rhamnosus GG-derived exosome-like nanoparticles (LDNPs) restored gut taurine
concentration through altering gut microbiota that led to the suppression of
miR194 and activation of FXR-FGF15 pathway, which suppressed BA de novo
synthesis and lipogenesis and alcohol-induced liver injury. Indeed, the beneficial
effects of LDNPs were eliminated in intestinal FxrΔIEC and Fgf15-/- mice.
To further investigate the mechanisms of LDNP’s overall beneficial effects in
ALD, we performed next-generation RNA sequencing (RNA-seq) in mouse liver
and ileum samples. An overarching comparative analysis of differentially
regulated genes was conducted. We identified both unique and shared molecular
mechanisms and signaling pathways for the treatment of ALD by LDNPs, which
can be a basis for future study.
In summary, our findings demonstrated that alcohol feeding increases intestinal
miR194 through gut microbiota-mediated taurine dysmetabolism resulting in a
suppressed Fxr gene expression and a decreased BA-mediated FXR activation,
which leads to BA accumulation and increased lipogenesis and injury in the liver,
and this can be inhibited by LDNP treatment. Moreover, transcriptomic analysis
identifies genes responsive to alcohol and LDNP treatment in the liver and
intestine in mice. The present study has shed light on the molecular mechanisms
of the intestinal miRNA regulation of hepatic BA synthesis and lipogenesis in
ALD and the protective effects of probiotic-derived extracellular vesicles.
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CHAPTER 1
INTRODUCTION

1.1 Overview of Alcohol-associated Liver Disease (ALD)
Alcohol-associated liver disease (ALD) represents a spectrum of liver injury
resulting from alcohol abuse, ranging from hepatic steatosis to more advanced
forms including alcohol associated hepatitis (AH), alcohol-associated cirrhosis
(AC) and even hepatocellular carcinoma (HCC) ALD is a major cause of liver
disease worldwide, both on its own and as a co-factor in the progression of
chronic viral hepatitis, nonalcoholic fatty liver disease (NAFLD), iron overload,
and other liver diseases. ALD develops through several stages, beginning with
hepatic steatosis, and, in some individuals, gradually progressing through AH
(the histological correlate of which is alcoholic steatohepatitis) culminating in
cirrhosis (Fig. 1.1) (1). ALD carries a significant stigma in society (2).
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Ekihiro Seki et al., Liver Res,

Figure 1.1 Progression of ALD. ALD is a term that encompasses the liver

manifestations of alcohol overconsumption, including fatty liver (steatosis), alcoholassociated hepatitis, and chronic hepatitis with liver fibrosis or cirrhosis, and
sometimes progressing to liver cancer, or hepatocellular carcinoma (HCC).

Chronic alcohol consumption, the consumption of large quantities of alcohol, and
specific drinking patterns are associated with the disease progression (Fig. 1.1).
Most patients with ALD do not develop cirrhosis even with long-term alcohol use.
Various factors influencing disease progression include gender, ethnicity, genetic
variants, viral hepatitis, and obesity (3). Approximately 90% of heavy drinkers
develop alcohol associated steatosis (4). This stage is reversible upon
withdrawal of alcohol. About 20%–40% of patients with alcohol associated
steatosis will progress to alcoholic steatohepatitis, which is histologically
characterized by the infiltration of inflammatory cells, especially neutrophils, the
appearance of Mallory-Denk bodies, ballooning degeneration, and hepatocyte
death in the liver parenchyma (5). Some of those patients will develop liver
fibrosis and subsequently cirrhosis. Fibrosis begins at perivenular region and
extends to the neighboring central or portal areas (bridging fibrosis). Cirrhosis
may further progress to HCC (5). AH, which can be an acute-on-chronic
condition of ALD, presents with clinical symptoms, such as jaundice, infection,
and decompensation.
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Accurate assessment of the full spectrum of ALD prevalence is challenging,
particularly given the difficulty with identifying earlier, asymptomatic stages of
ALD, such as moderate AH. The challenge may be overcome with broader use of
noninvasive steatosis and fibrosis assessment tools and increased awareness
for the need to diagnose early-stage disease (6). However, when the diagnosing
is unclear, a liver biopsy may be considered to exclude other causes of liver
disease.
Classic treatment of ALD includes abstinence, which is the most effective way to
manage ALD for subjects at early disease stage (7). Nutritional support,
corticosteroids, and liver transplantation are also used based on disease severity
and other complications (8, 9). Despite major progress made in the past decades
in understanding the pathogenesis of ALD and the improvement in ALD
management, currently there is still no FDA (Food and Drug Administration)
approved therapy for any stage of ALD. New targeted therapies for ALD are
urgently needed.
1.2 Role of farnesoid X receptor (FXR) and bile acids (BAs) in ALD
Alcohol consumption induces hepatic metabolic changes, increases oxidative
stress and alters lipid metabolism that leading to hepatotoxicity (10). The majority
of heavy drinkers develop simple steatosis, but only a small portion of the
patients progresses to more severe stages, including steatohepatitis, fibrosis and
cirrhosis (10). Notably, patients with ALD often exhibit manifestations of
cholestasis, a liver pathology characterized by accumulation of hepatic bile acids
(BAs) (11, 12). Dr. Lieber׳s group (13) first observed that chronic alcohol
consumption results in an increased BA pool and decreased excretion of BAs.
Recent study indicated that there was a possibility of increased BA synthesis in
AH patients even in the face of cholestasis and increased BA levels (14).
Increased BA level in serum of patients with ALD has been further demonstrated
by other studies recently (15) suggesting that alcohol consumption may affect the
BA circulation. BAs are detergent-like molecules that are metabolites of
cholesterol catabolism (16-18). BAs are synthesized and conjugated in the
hepatocytes and then secreted into the intestine to support the absorption of
dietary lipids, cholesterol, and fat-soluble vitamins (19). BAs are also signaling
molecules through binding to farnesoid X receptor (FXR). G protein-coupled bile
3

acid receptor 1 (GPBAR1; TGR5) receptor, and sphingosine-1-phosphate
receptor 2 (20, 21), which regulate many pathophysiology processes, including
BA homeostasis and lipogenesis.
FXR (gene name: Nr1h4) is a member of the steroid/thyroid hormone receptor
family of ligand-activated transcription factors, and certain BAs are its
endogenous ligands, either agonists or antagonists. In the liver, FXR plays a
prominent role in the feedback repression of BA synthesis via small heterodimer
partner (SHP) by reducing the expression of cytochrome p450 enzymes Cyp7A1
and Cyp8B1 to suppress BA synthesis (22). In the ileum, FXR is critically
involved in the BA reabsorption process through the regulation of BA transporter
expression. Activation of FXR in the ileum also induces the expression of
fibroblast growth factor (FGF)-15/19 (mouse/human), a hormone that is secreted
into the portal blood and transported to the liver, where it regulates multiple
signaling pathways to inhibit BA synthesis (23, 24). Thus, hepatic and intestinal
FXR coordinately regulate BA synthesis through inhibition of several P450
enzymes (Fig. 1.2). In addition to BA regulation, FXR-FGF15/19 also functions to
inhibit glucose synthesis, stimulate protein and glycogen synthesis, and repress
hepatic lipogenesis. Previous research demonstrated that FGF15/19 activates
SHP to recruit DNA methyltransferase-3a (DNMT3A) to lipogenic genes that
have been activated by sterol-regulatory element binding protein-1 (SREBP1),
resulting in DNA methylation and epigenetic repression of the lipogenic genes
(25).

4

Figure 1.2 FXR-mediated BA synthesis pathway in ALD. BA synthesis

is tightly regulated through enterohepatic signaling. FXR is a member of the
steroid/thyroid hormone receptor family of ligand-activated transcription factors,
and certain BAs are its endogenous ligands, either agonists or antagonists. In the
liver, FXR plays a prominent role in the feedback repression of BA synthesis via
small heterodimer partner (SHP) by reducing the expression of cytochrome p450
enzymes Cyp7A1 and Cyp8B1 to suppress BA synthesis. In the ileum, FXR is
critically involved in the BA reabsorption process through the regulation of BA
transporter expression. Activation of FXR in the ileum also induces the
expression of fibroblast growth factor (FGF)-15/19 (mouse/human), a hormone
that is secreted into the portal blood and transported to the liver to repress the
expression of Cyp7A1. Thus, hepatic, and intestinal FXR coordinate and regulate
BA synthesis through Cyp7A1 regulation.

Chronic alcohol exposure also alters the enterohepatic circulation of BAs. Alcohol
exposure increases the expression of BA efflux transporters including the bile
salt export pump (BSEP), multidrug resistance protein 4 (MRP4) and organic
solute transporter α/β (OSTα/β) and decreases the expression of BA uptake
5

transporter and sodium taurocholate co-transporting polypeptide (NTCP) in the
liver (26), indicating a possibility of increased hepatic BA efflux.
Hepatic BA homeostasis is tightly regulated through balancing BA efflux, uptake
and de novo synthesis. Because of the observed increase in hepatic BA efflux,
the alcohol-induced accumulation of hepatic BA may be attributed to increased
BA synthesis and BA absorption in the intestines. Indeed, in addition to the BA
de novo synthesis, as mentioned above, alcohol consumption increases the
expression of bile acid transporters including OSTβ and apical sodium dependent
bile acid transporter (ASBT) in the ileum (26). The transcriptional changes of BA
transporters in the ileum may result in increased absorption of BA into the portal
circulation.
Alcohol-induced disruption of the enterohepatic circulation has been attributed to
decreased FXR activity (27, 28). As shown in Fig 1.2, FXR negatively regulates
the expression of CYP7A1 and CYP8B1 but positively regulates the expression
of FGF15 (29, 30). These results suggest that FXR may be a potential
pharmacological target for alleviating alcohol-induced BA accumulation and liver
injury. Indeed, Dr. Szabo’s group found that FXR agonists ameliorate liver Injury,
steatosis, and inflammation after binge or prolonged alcohol feeding in mice (28).
Specifically, alcohol exposure increases CYP7A1 production in the liver, which
catalyzes the rate-limiting step in BA biosynthesis from cholesterol. In their ALD
models, treatment with OCA and INT-767, both of which signal through FXR (but
not INT-777), decreases CYP7A1 expression, confirming that administration of
these FXR agonists induces the expected effect in the liver of mice undergoing
alcohol-induced liver injury. Additionally, Dr. Schnabl’s group revealed that
modulation of the intestinal bile acid/FXR/FGF15 axis improves ALD in mice (27).
Metagenomics and bile acid analysis demonstrate functional consequences of
intestinal dysbiosis following chronic alcohol administration, including low FGF15
plasma levels, increased hepatic Cyp7a1 expression with disturbed bile acid
homeostasis, and changed hepatic lipid metabolism. Modulating dysregulated
bile acid signaling improves alcohol-induced liver disease in this preclinical
model. Fexaramine (an intestine restricted FXR agonist) and FGF19 are
therefore candidate drugs to treat alcoholic steatohepatitis in humans.
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In addition, FXR activation showed other mechanistic beneficial effects in the
liver. WAY and 6α-ethyl-chenodeoxycholic acid (6ECDCA) are potent FXRspecific agonists (31). Intriguingly, pharmacological activation of FXR by WAY
and 6ECDCA attenuated chronic alcohol-induced liver injury and steatosis (32,
33). FXR regulates sterol regulatory element-binding protein 1 (SREBP1) through
the SHP-liver X receptor (LXR) axis, in which SHP inhibits LXR activity resulting
in decreased expression of SREBP1 (34). Indeed, FXR activation by 6ECDCA
attenuated alcohol-induced steatosis by ablating SREBP1-mediated lipogenesis
(33). Furthermore, FXR activation also decreased alcohol-mediated reactive
oxygen species (ROS) production (33). The mechanism of how FXR activation
protects against alcohol-induced oxidative stress is currently not well elucidated.
However, WAY treatment decreased alcohol-mediated induction of CYP2E1,
which may play a role in attenuation of alcohol-induced oxidative stress (32).
Interestingly, in human hepatocyte-derived cell lines, the proximal promoter sites
of human alcohol dehydrogenase (ADH) isomers, ADH1A and ADH1B, have
functional inverted repeat 1 (IR1), a single stranded sequence of nucleotides
followed downstream by its reverse complement. It has been found that FXR
binds to the response elements and induces expression of ADH1A and ADH1B,
resulting in increased ADH1 enzymatic activity (35). However, FXR did not
induce ADH expression in rodent livers and hepatocytes, indicating that FXRmediated induction of ADH may be species specific (35). FXR may play a
protective role against human ALD by inducing ADH-mediated metabolism of
alcohol.
Transcriptional activity of FXR is primarily regulated by permissive binding of the
ligands, of which the most potent and abundant endogenous ligands are BAs.
BAs are released from the gallbladder when food enters the duodenum and
appear in the plasma 30 to 60 min postprandially (36). In the postprandial period
serum BAs therefore increase approximately 2-fold along with increases of BA
levels in the portal vein and liver (37). In the fasting state BA secretion from the
liver equals hepatic re-uptake of BAs (37). Of note, serum BAs oscillate in a
circadian rhythm (38) and are increased in the postprandial phase (39), while in
metabolic diseases such as obesity and NAFLD, BAs levels and FXR expression
are reduced (40).
7

The activity of FXR can be modulated on several levels (Fig 1.3).

Figure 1.3 Regulation of FXR activation. The presence of bile acids in

intestinal enterocytes activates the FXR, which induces expression of FGF15.
FGF15 binds and activates hepatic FGFR4, resulting in enhanced ERK signaling,
which coordinates with FXR-induced SHP to repress the expression of CYP7A1.
In response to these multiple bile acid-activated cellular signaling pathways,
interaction of FXR with transcriptional cofactors is changed, which results in
altered PTMs of FXR to effectively modulate expression at target genes. SHP,
Small heterodimer partner; RXR, Retinoid X receptor; FGFR4 ,Fibroblast Growth
Factor Receptor 4; PTM, Post Translational Modification.

Systemic activation of FXR was shown to protect against cholestasis via a
putative hepatic FXR-mediated effect (41). Interestingly, Fxr deficiency in mice
results in increased hepatic BA levels and liver injury including hepatic steatosis,
inflammation, and fibrosis (30, 42). Previous research using tissue-specific FXR
knockout mice demonstrated that the intestinal FXR-FGF15 pathway plays a
prominent role, with respect to the hepatic FXR-SHP pathway, in repressing
Cyp7A1 expression (43). Whole-body Fxr knockout in mice altered the BA pool
composition and exacerbated chronic ALD (44). However, hepatocyte restricted
8

deletion of FXR presented similar BA levels compared to WT mice and did not
affect the severity of ALD in mice (45), suggesting that intestinal FXR may play a
major role in BA homeostasis in ALD mice (27). It was also reported that alcohol
treatment suppressed expression of lipid oxidation genes in Fxr knockout mice,
which may contribute to exacerbated hepatic steatosis. Furthermore, alcohol
induced expression of CD14, the receptor for LPS (lipopolysaccharide), in Fxr
knockout mice with a higher degree in comparison to WT mice. Increased CD14
expression may exacerbate alcohol-induced liver injury by increasing the
sensitivity to inflammation (46).
While the FXR ligand activation has been well-studied, how FXR gene
expression is regulated remains incompletely understood. Previous research
demonstrated that intestinal SIRT1 impairs the transcriptional activity of HNF-1α,
leading to a decreased FXR signaling pathway and thereby reduced BA
absorption in the distal ileum and increased elimination of BA from feces (47).
Previous research has also demonstrated that hepatic miR194 regulates Fxr
mRNA expression in a mouse model of NAFLD (48). However, it is unclear
whether miR194 regulates intestinal Fxr in ALD.
In summary, these findings suggest that FXR plays a role in protecting the liver
from alcohol-induced hepatotoxicity likely by regulating BA de-novo synthesis
and metabolism, lipid metabolism and sensitivity to inflammation. The FXR-BA
axis may be a promising therapeutic target for ALD. More studies are needed to
further examine the role of FXR and BA in alcohol-induced hepatotoxicity,
cholestasis and steatosis.
1.3 Gut microbiome and ALD
The intestine harbors a diverse community of bacteria. Eubiotic bacterial
members of this community are beneficial for host metabolism and digestion,
thereby creating a symbiotic relationship with the host. Intestinal dysbiosis is
defined as an imbalance of the different microbial entities in the intestine with a
disruption of symbiosis (49). Intestinal dysbiosis can present as quantitative
(intestinal bacterial overgrowth) and qualitative changes in the intestinal
microbiota. Clinical and animal studies demonstrated that intestinal dysbiosis is
associated with ALD development and progression (50, 51). Alcohol exposure
9

damages gut epithelial barrier function that allows an increased translocation of
bacteria and endotoxin, which facilitate the development and progression of ALD
(52).
Recently, several groups have extensively reviewed the role of gut microbiome in
ALD recently (52, 53). ALD patients exhibit bacterial overgrow along the
gastrointestinal tract, which affects alcohol metabolism and results in increased
concentration of acetaldehyde (54, 55), which is high reactive and causes gut
epithelial cell damage. Dysbiosis usually increases gut bacterium-derived
endotoxin, which can be released to circulation due to the dysregulated gut
barrier functions (56). It has been well documented that alcohol consumption
causes elevated circulating endotoxin in experimental ALD in animals (56) and in
patients with ALD (57). Elevated endotoxin increases hepatic inflammation due
to the activation of Kupffer cells and subsequent toll-like receptor 4 (TLR4)mediated cytokine and chemokine production (52).
Patients with alcoholic associated cirrhosis have higher amount of
Proteobacteria, Prevotellaceae, and Veillonellaceae, and lower amount of
Bacteroidetes in the colon and feces compared to non-cirrhotic alcoholic patients
or healthy people (15, 58). Moreover, in several animal studies, alcohol-fed
animals had higher proportions of Verrucomircobia, Proteobacteria, and
Actinobacteria, and lower proportions of Firmicutes including Lactobacillus,
Pediococcus, Leuconostoc and Lactococcus (51, 59). However, multiple studies
showed inconsistence results regarding the changes of gut microbiota in ALD
subjects. One study showed that Bacteroidetes was elevated in chronic alcoholfed rats, whereas another study demonstrated that chronic alcohol feeding
decreased the proportion of Bacteroidetes (51, 59). These contradictory results
could be multi-factorial, and further studies are required to identify the
confounding factors that affect gut bacterial homeostasis in ALD.
Gut microbiota plays an essential role in BA metabolism (Fig 1.4), in which the
intestinal bacteria are involved in biotransformation of BA through deconjugation
and dehydroxylation (60). Briefly, the liver synthesizes two primary BAs from
cholesterol, cholic acid and chenodeoxycholic acid, which are conjugated to
either taurine or glycine before being entered into the bile flow. Conjugated BAs
are the primary components of bile, which is stored in the gallbladder before
10

being excreted into the small intestine during digestion. Over 95% of the BAs
secreted in bile are reabsorbed in the terminal ileum, and returned to the liver
through the enterohepatic circulation, while only 5% reach the large intestine,
and are excreted in feces. In the large intestine, BAs can undergo several
microbial-mediated transformations including deconjugation, carried out by bile
salt hydrolases (BSHs) that hydrolyze the amide bond, and transformation of
primary deconjugated BAs into secondary BAs mainly by a 7α-dehydroxylation
(Fig 1.4). Whereas deconjugation reactions are carried out by a broad spectrum
of colonic bacteria, 7α-dehydroxylation appears to be restricted to a limited
number of intestinal bacteria (61). Thus, the BAs profile excreted in feces, mainly
composed of secondary BAs, largely depends on the gut microbiota metabolism
(62).
Additionally, the perturbed BA profile may be attributed to gut bacterial
overgrowth, resulting in an altered BA deconjugation and subsequent taurine
metabolism (63). It is known that gut bacteria metabolize the majority of taurine
into inorganic sulfate, which results in a decreased of taurine bioavailability (64).
It is thus reasonable to hypothesize that alcohol-induced dysbiosis may cause a
deficiency of taurine in the gut. Previous studies showed that supplementation of
taurine protected against ALD in mice (65). The mechanisms of the action of
taurine in the gut warrants further investigation.
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Figure 1.4 Overview of enterohepatic circulation and microbial
processing of bile acids. Host-derived primary bile acids are synthesized by
heptocytes (CA and CDCA) and conjugated with either taurine or glycine. Primary
bile acids are then secreted into the bile and stored in the gallbladder
untilsecreted in the duodenum. Resident gut microbiota biotransform primary bile
acids into secondary bile acids such as LCA, UDCA, DCA and release free
taurine/glycine.

Conversely, BAs also regulate the gut flora via their antimicrobial activity (66).
Rats fed with a cholic acid (CA)-containing diet had increased gut Firmicutes to
Bacteroidetes ratio. Moreover, these rats displayed increased level of a toxic bile
acid, deoxycholic acid (DCA), in the cecum due to bacterial-mediated 7α
dehydroxylation of CA. DCA is toxic and selectively inhibits growth of gut bacteria
including Bacteroidetes and Lactobacillus, which results in altered gut microbiota
12

(67). Moreover, increased abundance of Firmicutes promotes the growth of DCAproducing bacteria (68). Alcohol consumption also increased DCA concentration
in the gastrointestinal tract (26). Patients with or without alcoholic cirrhosis who
are active drinkers exhibited increased secondary bile acids including DCA along
with decreased fecal Bacteroidetes (15). Additionally, chenodeoxycholic
acid CDCA, a bile acid whose conjugated form constitutes only 2% of the total
BAs that reach the gastrointestinal tract of mice, acts as a positive regulator of
the intestinal antimicrobial environment in vivo (69). CDCA increased the ileal
expression of genes from two major families of intestinal antimicrobial peptides
(AMPPs), namely, Paneth cell α-defensins and C-type lectins. Therefore, toxic
DCA and CDCA may play a role in alcohol-induced gut bacteria dysbiosis.
FXR activation by bile acids induced expression of genes involved in
enteroprotection and inhibited bacterial overgrowth and mucosal injury (70).
Conversely, Fxr KO mice displayed more severe bacteria overgrowth and
epithelial barrier deterioration (70).
In summary, it is clear that alcohol consumption causes gut dysbiosis that
regulates taurine and BA biotransformation, which may contribute the
pathogenesis of ALD. It remains unclear how these alterations regulate intestinal
FXR activation in ALD.
1.4 microRNAs and ALD
Small noncoding RNA, discovered by Ambros and colleagues in 1993 (71), are
small noncoding RNAs, 18–24 nucleotides in length, that regulate gene
expression by binding to mRNAs to interfere with the process of translation (72).
Genes that encode miRNAs are transcribed from DNA to a primary transcript
(pri-miRNAs), which is processed into a short precursor (pre-miRNA) and then
exported into the cytoplasm where it is further processed into a mature, single
stranded miRNA (72, 73) (Fig 1.5). Additionally, miRNAs are first transcribed
from miRNA genes via RNA polymerase II or III as primary miRNA (pri-miRNA)
and cleaved by the DROSHA–DGCR8 complex in the nucleus. The resulting
precursor (pre)-miRNA is exported to the cytoplasm via exportin-5 complex. In
the cytoplasm, DICER, along with TRBP, cleaves precursor miRNA (pre-miRNA)
to form mature miRNA (miRNA duplex). The strand is selected depending upon
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the stability, and the functional strand is loaded together with Ago2 and GW182
into the RNA-induced silencing complex (RISC). The less stable strand of miRNA
gets degraded. Depending on the complementarity of the seed region of mature
miRNA to the 3' UTR of the target mRNA gene, target mRNA undergoes
cleavage, translational repression or activation.

Gyongyi Szabo et al., Nat Rev Gastroenterol Hepatol. 2014

Figure 1.5 Biogenesis of miRNAs.
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miRNAs are abundant in the liver and modulate a diverse spectrum of cellular
processes associated with liver injury, such as inflammation, apoptosis, and
hepatocyte regeneration (69). Numerous studies have demonstrated the roles for
miRNAs in the pathogenesis of liver diseases (69, 74). Specifically, a large
number of studies have assessed the role of miRNAs in ALD and NAFLD (7577). Several miRNAs were found to be aberrantly expressed with alcohol
exposure. Although the predisposing risk factors and some etiologies of ALD
were varied, the deregulation of some specific miRNAs was commonly identified
in the published studies (78, 79), suggesting their importance in alcoholic liver
injury. Among these, the over-expression of miR-21, miR-34a, miR-155, miR-320
and the under-expression of miR-122, miR-181a, miR-199a, miR-200a were
reported by more than one publication. These miRNAs are described in Table 1.

Table 1. Most commonly dysregulated miRNAs in ALD.
miRNA

Dysregulation

References

miR-122

Decreased/Increased (78), (79)

miR-125b

Decreased

(79)

miR-126

Decreased

(80)

miR-155

Increased

(81), (82)

miR-181a

Decreased

(78), (77)

miR-199a

Decreased

(82), (77)

miR-200a

Decreased

(77), (79)

miR-21

Increased

(78), (83)

miR-217

Increased

(84)

miR-320

Increased

(77)

miR-34a

Increased

(78), (79)

miR-375

Increased

(85)

miR-486

Increased

(77)

let-7b

Decreased

(78)
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Previous study in our group showed that chronic alcohol exposure increased
intestinal miR122a expression, which decreased intestinal tight junction protein
occludin expression leading to increased intestinal permeability (86). Similar to
the effect of alcohol exposure, overexpression of miR122a in Caco-2 monolayers
markedly decreased occludin protein levels. In contrast, inhibition of miR122a
increased occludin expression. Another study (87) shows that alcohol increased
intestinal miR212 expression, decreased ZO-1 protein levels, disrupted tight
junctions, and increased the permeability of monolayers of Caco-2 cells. A
miR212 over-expression is correlated with hyperpermeability of the monolayer
barrier. miR212 levels were higher, while ZO-1 protein levels were lower in colon
biopsy samples in patients with ALD than those in healthy controls. Importantly,
alcohol consumption, with or without concurrent ALD, has also been linked to
altered expression of several miRNAs (77).
In animal models of mice fed with alcohol via intragastric alcohol feeding or 5
weeks Lieber Decarli alcohol feeding, the levels of hepatic miR-21 were found to
be differentially overexpressed in mice fed with alcohol compared to pair-fed
controls (88). The induction of hepatic miR-21 is believed to exert its protective
effect against liver injury secondary to alcohol. First, overexpression of miR-21
increases cell survival during alcohol-induced liver injury (88). Second, AH and
AC lead to alterations of tissue repair; a process involving a series of death
receptor signaling pathways (89). miR-21 is a putative mediator of hepatic
damage and crucial in tissue repair during alcohol exposure (88). Third, miR-21
may serve as a key regulator of liver regeneration in response to liver injury
secondary to alcohol consumption (89).
Extracellular vesicles, including microvesicles, exosomes and apoptotic bodies
are released from almost all cell types into the microenvironment, and are
involved in physiological function and the pathology of different diseases (90). Dr.
Szabo’s group (91) found a significantly increased number of circulating EVs in
sera of alcohol-fed mice compared to pair-fed mice. Similarly, they observed a
significantly increased number of EVs in plasma of AH patients, compared to
healthy controls. Nine deregulated inflammatory miRNAs were found in
exosomes of alcohol-fed mice. Particularly, miRNA-122, miRNA-30a, and
miRNA-192 showed the most substantial increases and had an excellent
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diagnostic value for differentiating alcohol-fed mice from pair-fed mice.
Importantly, of these miRNAs in the cohort of patients with AH. they found a
significantly elevated level of miRNA-30a and miRNA-192 in the EV-fraction of
plasma. This observation in human AH validated their findings in the animal
model and indicates that the chronic Lieber DeCarli alcohol feeding model
partially presents similar features of human AH. Additionally, Dr. Schnabl’s group
found the EVs released by hepatocytes from animals with the gastric infusion
model of ALD contain a miRNA signature that can be detected in blood
uncovering miRNAs as a potentially novel diagnostic tool for ALD patients (92).
Over the last years, an increasing number of miRNAs have been proposed as
potential biomarkers of ALD. The following is a review of the most promising
results.
miR-27a: miR-27a has been linked to monocyte differentiation and is increased
in extracellular plasmatic vesicles of patients with AH, making it a potentially
useful diagnostic tool (93).
miR-182: An elevated level of miR-182 has been linked to greater disease
severity and liver injury in AH. The correlation between miR-182 and disease
severity, however, has only been shown in liver biopsies, limiting its application
as a diagnostic tool (76).
miR-103 and miR-107: A prior study found that miR-103 and miR-107 were
increased in liver from patients with ALD and with NAFLD, but not in healthy
livers or in subjects with viral hepatitis (94).
miR-155: Increased blood levels of miR-155 (75, 95) have been found in healthy
individuals after binge drinking and in a murine model of liver damage. While
these miRNAs could be potential biomarkers of alcohol intake or alcohol liver
damage, they are increased in several types of liver disease and therefore are
unlikely to be specific to ALD (75).
While the majority of studies of miRNA regulation in ALD involves serum and
hepatic tissues, the intestinal miRNA regulation in ALD has not received
sufficient investigation. Additionally, how miRNA regulate transcriptional factors,
such as FXR, in the intestine tissue of ALD subjects has not been investigated.
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1.5 Probiotics and ALD
According to the FAO/WHO definition, probiotics are defined as “live
microorganisms which, when administered in adequate amounts, confer a health
benefit on the host”. Probiotics have been used as interventions in the
management of ALD in patients and in experimental animals acting through
multiple mechanisms (50, 51, 96). Ideal probiotic strains for this kind of
application should be resistant to bile, hydrochloric acid, and pancreatic juice; be
able to tolerate stomach and duodenum conditions and gastric transport; and
have the ability to stimulate the immune system, thereby improving intestinal
function via adhering to and colonizing the intestinal epithelium. In addition,
probiotic strains must be able to survive during manufacture and storage in order
to exert considerable healthful outcomes (97). Currently, the most often used
probiotics are Bifidobacteria, lactic acid bacteria (LAB), Propionibacteria, yeasts
(Saccharomyces boulardii), and the Gram-negative Escherichia coli strain Nissle
1917. Lactobacilli, major contributors to the LAB group, are frequently used
probiotics. Various species and strains of Lactobacilli have been used in the
practice in animals and humans, including Lactobacillus acidophilus,
Lactobacillus casei, Lactobacillus rhamnosus, and Lactobacillus helveticus. Most
of these species belong to the phylum Firmicutes. Bifidobacterium, which
produces lactic acid, is another commonly used probiotic genus and belongs to
the Actinobacteria phylum. To date, a large number of probiotics have been
reported to be suitable for the treatment of a variety of diseases, and this number
is still growing.
Accumulating evidence demonstrates the protective effect of probiotics on
multiple pathological disorders. Recently, we evaluated the effectiveness of the
probiotic Lactobacillus rhamnosus GG (LGG), a Gram-positive bacteria which is
well-recognized for its advantageous effects including immunoregulation, lipid
modulation, and gene expression in diseases such as ALD, NAFLD,
inflammatory bowel disease and neuronal disorders, in the prevention of acute
and chronic alcohol-induced hepatic steatosis and liver injury (86, 98, 99).
However, these treatments are not always effective because, in many cases, live
bacteria must colonize the gut to confer their beneficial effects. The spectrum of
pathogenic bacteria varies from patient to patient. Drugs, in particular antibiotics,
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used by patients may be harmful to live probiotics. Therefore, an unstable and
variable effect of live probiotics may occur. Moreover, the clinically recommended
dose of probiotics usually consists of billions of live bacteria. Generally, probiotics
are considered safe, but several reports have raised safety concerns about
ingesting such large amounts of bacteria, especially when the intestinal function
and the patient's immune response are compromised (100, 101). In fact, soluble
factors secreted from probiotics and dead probiotics have been used in the
treatment of several diseases’ conditions such as inflammatory bowel disease,
colitis, and arthritis (102, 103). Probiotics and prebiotics including Lactobacillius
feedings alleviated alcohol-induced liver injury and restored the gut microbiota in
both animal models and patients with ALD (50, 51). Yan et al. demonstrated that
soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell
survival and growth (104). Interestingly, the beneficial effects of probiotics on
ALD appear to not be restricted to viable probiotic bacteria. Segawa and
colleagues demonstrated that oral administration of heat-killed Lactobacillus
brevis SBC8803 induced the expression of cytoprotective heat shock proteins
and improvement of intestinal barrier function leading to amelioration of
experimental ALD (105). We showed that pretreatment with LGG supernatant
(LGG-s) reduced hepatic fat accumulation in mice subsequently exposed to
acute-binge alcohol (98). Furthermore, co-administration of LGG supernatant
with alcohol in the Lieber-DeCarli liquid diet for 4 weeks significantly attenuated
alcohol-induced intestinal barrier dysfunction, endotoxemia, fatty liver, and
inflammation in mice (86, 99). The use of probiotic culture supernatant opens a
new avenue for the probiotic application. Further characterization of the LGG-s
active components will enhance our understanding of the protective effect of
probiotics in ALD and advance the development of new therapeutic strategies for
ALD.
Soluble proteins produced by LGG have been shown to regulate intestinal
epithelial cell survival and growth (106) and molecules produced by LGG with
different effects on the host have been described (107, 108). How these
individual products are released from bacteria and interact with the host
cells/bacteria is not clear. Bacteria, along with mammalian cells, release
exosome-like nanoparticles (ELNPs), which are implicated in bacterial cell–cell
interactions and bacterial cell–host cell communications (109). ELNPs carry a
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variety of genetic materials (miRNA, mRNA, and other noncoding RNAs),
proteins, and metabolites (110). Previous studies suggest that ELNPs function as
natural effectors of signaling between cells Gram-negative bacteria can produce
ELNPs, and that Gram-positive bacteria are not able to produce ELNPs due to
their thick cell wall. However, recent studies showed that Gram-positive bacteria
can, in fact, also release ELNPs (111, 112). It has been shown
that Lactobacillus-derived ELNPs have multiple functions, including stimulating
the host nervous system, inducing hepatic cancer cell death, and enhancing the
immune response against pathogenic bacteria (111, 113). We have already
shown that nanoparticles released from LGG (LGG-derived exosome-like
nanoparticles, LDNPs) contribute to the protective effects of LGG against
experimental ALD (114). The effects of LDNPs are mediated through the delivery
of the specific cargo material to intestinal cells to protect barrier integrity. LDNP
treatment increases the expression of antimicrobial peptides (Reg3β and Reg3γ)
and intestinal tight junction proteins in cultured intestinal epithelial cells and in
intestinal tissue of mice fed alcohol. We further showed that the LDNPs were
enriched in bacterial tryptophan metabolites, indole derivatives, which are
endogenous aryl hydrocarbon receptor (AhR) agonists. We also showed that
LDNPs protected against experimental ALD through intestinal AhR-IL22-Reg3related and nuclear factor erythroid 2-related factor 2 (Nrf2)–mediated signaling
pathways, leading to reduced bacterial translocation and lipopolysaccharide
(LPS) release.
Importantly, our recent studies have also demonstrated that LGG decreases
hepatic BAs by increasing intestinal FXR–FGF15 signaling pathway–mediated
suppression of BA de novo synthesis and enhancing BA excretion in mice, which
have undergone bile duct ligation (BDL), and in multidrug resistance protein 2
knockout (Mdr2−/−) mice (115). However, whether LDNPs regulate BA
homeostasis in ALD is unknown.
Despite many proof-of-effectiveness studies of probiotics on the treatment of
both experimental and human ALD, the mechanisms of function of probioitcs are
still poorly understood. To date, several important mechanisms including the
modification of gut microbiota, improvement of the intestinal epithelial barrier
function, regulation of the immune system and inflammation, and alteration of
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hepatic lipid homeostasis have been proposed. These mechanisms involve gene
expression regulation in both intestinal and hepatic tissues. To our knowledge,
no study has explored the global gene expression patterns in ALD under
probiotic treatment. It will be important to identify both unique and shared
molecular mechanisms and signaling pathways for LDNP on treatment of ALD.
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CHAPTER 2
LACTOBACILLUS RHAMNOSUS GG-DERIVED EXOSOME-LIKE
NANOPARTICLES INHIBIT ALCOHOL-ASSOCIATED LIVER DISEASE
THROUGH INTESTINAL FXR ACTIVATION IN MICE: ROLE OF MIR194 AND
BILE ACIDS

2.1 Introduction
Patients with alcohol-associated liver disease (ALD) often exhibit manifestations
of cholestasis, a liver pathology characterized by accumulation of hepatic bile
acids (BAs). Excess BAs can be toxic and can be an important causative factor
in liver injury and hepatocyte death (11, 116). BAs are end products of
cholesterol catabolism and are made and released by the liver and stored in the
gallbladder. Due to their detergent-like functions, BAs play critical roles in
solubilization and absorption of cholesterol, dietary lipids, and fat-soluble
vitamins in the intestine. BAs can also act as signaling molecules through
activation of several receptors, including farnesoid X receptor (FXR), Takada-Gprotein receptor 5 (TGR5), and sphingosine-1-phosphate receptor 2 (S1PR2)
(117). FXR, highly expressed in the liver and intestine, is a BA-sensing nuclear
receptor that regulates many biological functions, including BA homeostasis and
lipogenesis.
BA synthesis is regulated by FXR in the liver and intestine. In the liver, BAs
activate FXR and upregulate small heterodimer partner (SHP), which functions
as a suppressor of the expression of genes encoding cholesterol 7α-hydroxylase
(Cyp7a1) and sterol 12α-hydroxylase (Cyp8b1), resulting in decreased BA de
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novo synthesis. In the intestine, BA-activated FXR upregulates fibroblast growth
factor (FGF) 15/19 (mouse/human) and promotes FGF15/19 secretion into the
portal vein, which leads to suppression of Cyp7a1 transcription and BA
synthesis. Global FXR knockout mice have increased hepatic BA levels and liver
injury (118). However, hepatocyte-specific FXR deletion does not change the BA
pool and the enzymes for BA de novo synthesis (45), suggesting that intestinal
FXR is a major player in regulating hepatic BA synthesis. Indeed, administration
of intestinal FXR agonists reduced hepatic BA levels in murine models of ALD
(27, 28).
While the FXR ligand activation has been well-studied, how FXR gene
expression is regulated remains incompletely understood. Previous research
demonstrated that hepatic microRNA194 (miR194) regulates Fxr mRNA
expression in a mouse model of NAFLD (48). However, it is unclear whether
miR194 regulates intestinal Fxr in ALD.
Probiotics have been used as interventions in the management of ALD in
patients and in experimental animal models (50, 51, 96, 119-121). Our previous
studies demonstrated that Lactobacillus rhamnosus GG (LGG) supplementation
decreases hepatic BAs by increasing intestinal FXR–FGF15 signaling pathway–
mediated suppression of BA de novo synthesis and enhancing BA excretion in
mice, which have undergone bile duct ligation (BDL), and in multidrug resistance
protein 2 knockout (Mdr2−/−) mice (115). Most recently, we found that LGGderived exosome-like nanoparticles (LDNPs) were protective against ALD in a
mouse model (114). However, whether LDNPs regulate BA homeostasis in
human ALD is unknown.
The present study was designed to investigate the how intestinal Fxr gene is
regulated and FXR is activated by alcohol in ALD mice. Our findings
demonstrated that alcohol feeding increases intestinal miR194 through gut
microbiota-mediated altered taurine dysmetabolism resulting in a suppressed Fxr
gene expression and a decreased BA-mediated FXR activation, which leads to
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BA accumulation and increased lipogenesis and injury in the liver, and this can
be inhibited by LDNP treatment.
2.2 Materials and Methods
2.2.1 Animal study
All animal protocols were approved by the Institutional Animal Care and Use
Committee of the University of Louisville. Male C57BL/6J mice (8 weeks of age)
were obtained from Jackson Laboratory (Bar Harbor, ME). Fgf15-/- and FxrΔIEC
mice (7 weeks of age) were provided by Rutgers University. They were
maintained at 22°C with a 12-hour:12-hour light/dark cycle and had free access
to normal chow diet and sterile water.
Mice were fed the Lieber DeCarli Diet containing 5% alcohol (w/v) (Alcohol-fed,
AF) or isocaloric maltose dextrin (Pair-fed, PF). For the AF groups, mice were
initially fed the control Lieber-DeCarli liquid diet (Bio-Serve, Flemington, NJ) for 5
days to acclimate them to the liquid diet. The content of alcohol in the liquid diet
was gradually increased from 1.6% (w/v) to 5% (w/v) in the next 6 days and
remained at 5% for the subsequent 10 days. Mice in PF group were fed
isocaloric maltose dextrin in substitution for alcohol in the liquid diet. On
experimental Day 10, a bolus of EtOH (5 g/kg body weight) was given to AF mice
by gavage 9 hours before harvesting, while mice in PF groups received a gavage
of isocaloric maltose dextrin (10D+1B model). LDNPs were administered to mice
in the last 3 days by daily gavage of 200 µL of LDNPs (50 µg protein content).
2.2.2 AH patients’ information
Patients with alcohol associated hepatitis (AH) and healthy controls (HCs) were
included in this clinical study. This investigation is part of a large national multisite
clinical trial (clinicaltrials.gov: NCT01809132) supported by the National Institute
on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health,
Bethesda MD. This study was approved by the institutional review board
(protocol No.12.0427) of the University of Louisville. All patient participants were
diagnosed with AH. Patients were 21 to 66 years of age, completed the
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consenting process for participation in the study, and did not have active drug
abuse. HCs were of similar age and did not have liver disease or any comorbid
conditions (heart, kidney, lung, neurologic or psychiatric illness, sepsis), and
none had any acute or chronic inflammatory process. Pregnant and lactating
women, prisoners, and other individuals with potential vulnerability were
excluded from the study.
2.2.3 Patients’ stool samples collection
Research stool samples were collected along with the other morning routine and
research samples (blood and urine) for the study participants. Stool samples
were gathered in the 30 ml leak-proof vial Para-Pak kit (CS 120 - Meridian
Biosciences, Inc.), transported to the research laboratory, aliquoted into smaller
portions (volume by the requirements of the assigned study projects) and frozen
at -80°C. This whole process was completed within approximately two hours from
the collection time.
2.2.4 Chemical and biological reagents
Antibodies against CYP7A1, FXR, β-actin and Histone H3 were purchased from
Abcam (Cambridge, MA). SHP and SREBP-1c antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). CYP8B1 antibody was obtained
from Bioss (Woburn, MA). Reagents used for Real-time PCR were purchased
from Thermo Fisher Scientific (Waltham, MA). ALT, AST and TG assay Kits were
purchased from Thermo Fisher Scientific. Bile acid assay kit was purchased from
Diazyme (Poway, CA).
2.2.5 Serum biochemical analysis
Serum was collected from whole blood sample by centrifugation at 4000 g for 30
min at room temperature. Serum ALT, AST and liver TG were measured by using
standard laboratory assays.
2.2.6 LGG Culture and LDNP Isolation
LGG was purchased from American Type Culture Collection (ATCC 53103,
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Rockville, MD) and cultured in autoclaved deMan, Rogosa and Sharpe (MRS)
broth at 37°C for 40 hours. The culture density was measured with a
spectrophotometer at OD600. The culture suspension (2 × 109 CFU/mL) was
centrifuged at 2,000g for 10 minutes, at 5,000g for 20 minutes, and then at
10,000g for 30 minutes to eliminate debris including dead cells and other waste
materials. The obtained supernatant was filtered and ultracentrifuged at
150,000g for 70 minutes (Optima L-100XP Ultra Centrifuge; Bechman Coulter,
Atlanta, GA). After ultracentrifugation, the supernatants were collected and
stored, and the pellet containing LDNPs was washed in phosphate-buffered
saline (PBS), ultracentrifuged, resuspended in PBS, and stored at −80°C for later
use.
2.2.7 Serum exosome isolation
Exosomes were isolated by the using ExoQuick-TC® (System Biosciences Inc.,
Palo Alto, CA, USA) according to the manufacturer’s instructions. In brief, the
serum was centrifuged at 2000 g for 30 min and supernatant was collected. Onefifth of ExoQuick-TC Exosome Precipitation Solution and their suspension was
incubated overnight at 4 °C. The suspension was centrifuged at 1500 g for 30
min for ExoQuick-TC or at 10,000 g for 60 min for Total Exosome Isolation. The
pellet was resuspended with PBS. Exosome protein content was assessed using
the BCA protein assay kit (Thermo Fisher Scientific) before further experiments.
2.2.8 Isolation of intestinal mucus and crypt derived exosomes.
Mice were euthanized and the small intestine tissues were removed. The luminal
contents of the intestine were removed by gently flushing the intestine with 10 ml
of ice-cold PBS. The intestine was then opened longitudinally, the mucus was
collected by mild physical separation using round forceps and soaked in PBS
before agitating on a rotator at 500 g/min for 15 min. The mucus-PBS mixture
was processed by differential centrifugation for exosome isolation. For cryptderived exosome isolation, the intestinal segments were transferred to a clean
dish containing 15 mL of fresh, cold (2 - 8°C) PBS. The intestinal segments were
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rinsed in PBS buffer thoroughly and cut into 2 mm pieces. 15 mL cold PBS was
added to a 50 mL conical tube. Then, using scissors, the intestine tissue was cut
the intestine tissues into 2 mm pieces. Next, collecting these pieces falling into
the tube and centriguging at 200 g for three minutes at 2 - 8°C and the pelleted
intestinal crypts were harvested. The crypts were cultured in the DMEM overnight
and the exosomes in the culture media were isolated by ultracentrifugation.
2.2.9 miRNA isolation and quantification
miRNA was isolated using the mirVana™ miRNA Isolation Kit (Ambion, Austin,
TX, USA) according to the manufacturer's instructions. The purity and quantity of
RNA were assessed using the NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). All the samples were diluted to a final
concentration of 10 ng/μl. The samples were used immediately or stored at
−80 °C for future use.
2.2.10 Real-time polymerase chain reaction (Real-time PCR)
Total RNA was isolated by Trizol according to the manufacturer’s protocol. Total
RNA was used for reverse transcription with the cDNA cycle kit (Invitrogen).
Primers used in the experiments are listed in Tables 2 and 3. 18S and GAPDH
were used as internal controls. Real-time PCR was performed by using SYBR
green reaction mixture in the ABI 7300 fast real-time PCR system (Applied
Biosystems). The relative gene expression was determined by the ΔΔCT method.
TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA) was used for preparation of cDNA from miRNA. RT reactions were
performed in a volume of 15 μl, and each reaction contained 10 ng of total RNA.
RT reactions were performed on a GeneAmpPCR System 9600 (Applied
Biosystems) with the following conditions: 16 °C for 30 min, 42 °C for 30 min,
85 °C for 5 min, and 4 °C on hold. Reactions without addition of reverse
transcriptase (RT (−) controls) were performed alongside with cDNA synthesis of
each sample and used in subsequent procedures to control the potential
genomic DNA contamination. 1 μl of RT reaction product was added in the 20 μl
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qPCR reaction. All TaqMan assays were run in triplicate on an ABI Prism 7500
using TaqMan® Universal PCR Master Mix II without UNG (Applied Biosystems).
Real-time PCR cycling conditions consisted of 95 °C for 10 min, followed by 50
cycles of 95 °C for 15 s and 60 °C for 1 min. The Ct is defined as the PCR cycle
at which the fluorescent signal of the reporter dye crosses an arbitrarily placed
threshold in the exponential phase. For our assays, the constant threshold value
was set to 0.200 for easy comparison of results within and between assays. The
sample with a Ct value over 40 or an amplification point not reaching the
threshold was considered as invalid and was not useful for further analysis.
snRNA (U6b) assay functioning as reference gene to evaluate Ct values
2.2.11 Histological analysis
Liver sections from paraffin-embedded tissues were prepared at 5-μm thickness.
Liver pathology was examined by haematoxylin and eosin staining (H&E).
Samples were then mounted with CC/Mount (Sigma, St. Louis, MO).
2.2.12 Western blotting analysis
Liver tissues were homogenized, and then western blot analysis was performed.
Membranes were probed by using related antibodies. The blots were developed
by using ECL Western blotting reagents and quantified by using optical
densitometry. The intensity of each signal was corrected by the values obtained
from the immune-detection of β-actin, and the relative protein intensity was
expressed as fold of the content in the PF group.
2.2.13 Cell culture
Human intestinal epithelial cells Caco-2 were maintained in DMEM-high glucose
and EMEM-high glucose (Corning; 10-009CV) respectively. The medium was
supplemented with 10% fetal bovine serum, 1X penicillin-streptomycin solution
(100U/ ml penicillin, and 100µg/ml streptomycin; Sigma Aldrich) in a humidiﬁed
atmosphere (5% CO2, 95% air, 37°C). Cells were utilized for experimentation at
70-80% confluence. Caco-2 cells were treated with LDNPs (0.2 ug/ml) and 100
nM miR194 mimic or mimic control for 24 hours.
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2.2.14 3D organoids culture
Small intestines of C57BL6 mice were dissected and washed several times in
cold PBS. Intestinal fragments were incubated in 25 mL of Gentle Cell
Dissociation Reagent (GCDR) [STEMCELL Technologies Inc. (STI)] on a rocking
platform (20 rpm) at room temperature for 20 minutes, after which the fragments
were allowed to settle by gravity and supernatants removed. Intestinal pieces
were suspended in 10 mL cold PBS + 0.1% BSA by pipetting up and down
several times. The intestinal pieces were again allowed to settle by gravity and
the supernatants were collected, passed through 70 µm filters and kept on ice
(fraction 1). This process was repeated three times to generate fractions 2 - 4.
The quality of each fraction was assessed using an inverted microscope and
selected fractions were centrifuged. Crypts were then resuspended in cold
DMEM/F-12 (STI), counted, aliquoted into 15 mL tubes in volumes containing
500 - 3000 crypts and centrifuged. Crypts were resuspended in a 50:50 mixture
of complete IntestiCultTM Organoid Growth Medium (Supplement 1, Supplement
2 and 100 units/100 µg per mL penicillin/streptomycin) (STI) and Corning
Matrigel® at 1,667 - 10,000 crypts/mL, and 50 µL/well of the suspension was
pipetted into pre-warmed 24-well plates to form domes containing 80 - 500
crypts. The domes were solidified at 37 oC for 10 minutes before complete
IntesticultTM Organoid Growth Medium was added (750 µL/well). Cultures were
incubated at 37 oC, 5% CO2, for 7 - 10 days before passaging, with medium
changes 2 - 3 times per week. In some instances, organoids cryopreserved using
CryoStor® CS10 were thawed and used to initiate cultures as described above.
2.2.15 FXR reporter assay
HEK293 cells (ATCC) were maintained in DMEM containing 10% FBS and 100U
penicillin/streptomycin. Cells were seeded into 24 well plates at a density of
1x105 cells per well and transfected at 40-60% confluence. For FXR
transactivation assay, the transfection mixes per well contained 10 ng βgalactosidase expression plasmid (pCMV-β, Stratagene, CA) as a transfection
control, 50 ng FXR expression plasmid, and 100 ng FXR reporter plasmid. All
29

cells were co-transfected by lipofection using Lipofectamine reagent according to
the manufacturer’s instructions using Opti-MEM (reduced serum medium) as the
transfecting medium. After 4 h incubation, the medium was changed to DMEM
supplemented with 10% FBS and 1% antimycotic/antibiotic solution and cells
were allowed to recover, overnight. Resuspend 100 mg of fecal samples in 500
µL of sterile 1x Dulbecco's Phosphate-Buffered Saline (DPBS), centrifuge at
1,500 x g for 5 min at RT and collect the fecal supernatant. The cells were
stimulated 6 h with CDCA (20 μM) alone or in combination with serum (10ul) and
fecal supernatant (20ul). Luciferase activity was assayed in an Amersham
Pharmacia Biotech luminometer by using Reporter Assay System (Promega,
Madison, WI) according to the manufacturer's directions. Firefly luciferase and βgalactosidase in same sample simplifies normalization of transfection efficiency.
2.2.16 Analysis of microbiota from feces by Real-time PCR assay.
Total DNA was isolated and purified from caecum content by using the QIAamp
DNA Stool Mini Kit (Germantown, MD). The quality of DNA samples was
assessed by gel electrophoresis, and spectrophotometry at 260 and 280 nm.
Only DNA samples of sufficient quality were subjected to PCR. Real-time PCR
assay of Actinobacteria, Firmicutes and Bacteroidetes was performed as
previously described. 16S was used as an internal control. The specific primers
used for these groups were indicated in Table 4.
2.2.17 Bile acid analysis
BAs in samples were extracted by solid phase extraction (SPE) as described
previously. Specifically, serum was first mixed with acetonitrile ACN in a ratio of
1:4 (v:v). Then the mixture was centrifuged at 14000 g for 20 min at 4 oC after
being vortexed for 2-3 min. 200 µL of supernatant was transferred into a fresh
tube and lyophilized overnight. Each dried sample was reconstituted in 200 µL
water (pH ≥ 8.5) and then loaded onto an OASIS HLB cartridge (Waters Corp.,
Milford, MA, USA) that had been activated and equilibrated with alcohol and
water (pH ≥ 8.5) following the manufacturer’s instructions. The cartridge was
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washed with 1 mL of dH2O (pH ≥ 8.5) three times and then eluted three times
with 100 µL 70% of ACN (pH ≥ 8.5). The eluate was combined and lyophilized
overnight. The residue was then reconstructed in 50% ACN. The sample was
then centrifuged at 14,000 g for 20 min at 4 °C. The clear upper solution was
transferred to an LC vial for LC-MS analysis. Group-based pooled samples were
also prepared by mixing a small portion of the supernatant of each sample in the
same group.
To extract BAs from liver samples, the liver tissue was first homogenized in dH2O
in a ratio of 1:10 (mg: µL). 100 µL of the homogenized liver sample was mixed
with 400 µL of ACN. After a vigorous vortex, the mixture was centrifuged at
14,000 g for 20 min at 4 °C. Then, 400 µL of supernatant was transferred to a
fresh tube and lyophilized overnight. The remaining steps of SPE are identical to
those of processing serum samples as described above.
Fecal samples were homogenized in 80% ACN in water in the ratio of 1:10
(mg:µL). The remaining steps were the same as those for liver samples, except
200 µL of supernatant was used for freezing dry.
The standards of 46 bile acids were purchased from Cayman Chemical
Company (Ann Arbor, MI, USA) and Steraloids Inc. Company (Newport, RI,
USA). A stock solution of each bile acid standard was prepared at a
concentration of 5-10 mmol/L in alcohol. The stock solutions were kept in the
dark at -80 °C until use. A total of 12 calibration solutions were then prepared
using the stock solutions for each bile acid with the following concentrations:
0.0075, 0.0157, 0.0315, 0.0625, 0.125, 0.25, 0.5, 1.0, 2.5, 5.0, 10, and 20
µmol/L. All of the calibration solutions were prepared in 50% ACN.
A Thermo Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer
coupled with a Thermo DIONEX UltiMate 3000 UHPLC system (Thermo Fisher
Scientific, Waltham, MA, USA) was used in this study. The UHPLC system was
equipped with a Cortecs T3 column (100 × 2.1 mm i.d., 1.8 µm) purchased from
Waters (Milford, MA, USA). The temperatures of the column and autosampler
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were set to 60°C and 12°C, respectively. LC-MS methods for analyses of the
solutions of bile acid standards and BA extracts were the same as described
previously (1). All BA samples were analyzed by LC-MS in random order under
positive mode to obtain full MS data for their quantification. The group-based
pooled samples were analyzed by LC–MS/MS in negative mode to acquire
MS/MS spectra at three collision energies (20, 40, and 60 eV) for BA
identification.
The LC-MS/MS data of the pooled samples were used to identify BAs by
matching their experiment data with the corresponding information of the 46 BA
standards recorded in our in-house database that contains parent ion m/z,
MS/MS spectra, and retention time. The MS/MS spectrum similarity threshold
was set as ≥ 0.4, and the thresholds of the retention time difference and m/z
variation window were set as ≤ 0.15 min and ≤ 5 ppm, respectively. Thermo
Scientific Xcalibur instrument control software Quan (2.2 SP1.48) was used to
process the LC–MS data for peak picking, standard curve construction, and BA
quantification. The signal-to-noise ratio (S/N) was set to S/N ≥ 3. The
concentration of each BAs in a biological sample was calculated using the
calibration curve constructed from the LC–MS data of a corresponding BA
standard.
2.2.18 Fecal taurine measurement
Taurine Assay Kit (ab241040) was used to measure the fecal taurine
concentration according to the manufacturer’s instruction. Briefly, dissolve the
fecal samples in PBS (pH 7.4) by sonication. Then, the samples were dissolved
and supernatant was obtained. Next, the standard curve was prepared as well as
the enzyme mix and were added to all wells except background control, (add
assay buffer instead). The sulfite probe was added to the sample, background
control and standard wells, and incubated for 5 mins. Absorbance was measured
in an endpoint mode at 415 nm using a microplate reader.
2.2.19 Fecal BSH activity
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BSH activity was measured by determining the amount of amino acids liberated
from conjugated bile salts as previously described with several modifications
(122). Bacterial BSH activity was measured based on the generation of CA from
TCA in the feces. Brieﬂy, fecal protein extract was prepared from 0.5 g of fecal
samples in 1 mL of PBS (pH 7.4) by sonication. Then, the sample was
centrifuged and 1mL of supernatant was obtained, incubation was carried out by
adding 1.8 mL PBS and 0.1 mL 0.1mol/L TCA. After a 30 min incubation at 37°C,
reactions were stopped by adding 0.1 mL CCl3COOH for 1min, Then, the mixture
was centrifuged and 1mL of supernatant obtained was added to 1mL of 2mol/L
trichloroacetic acid buffer and 1mL of ninhydrin reagent (0.5 mL of 1% ninhydrin
in 0.5M citrate buffer pH 5.5, 1.2mL of 30% glycerol, 0.2mL of 0.5M citrate buffer
pH 5.5). The preparation was vortexed and boiled for 15 min. After subsequent
cooling, 3 ml potassium iodate (KIO3) was added, and the absorbance at 570 nm
was determined using taurine as standard. One unit of BSH activity was defined
as the amount of enzyme that liberated 1 mmol of amino acid from substrate per
min.
2.2.20 Transient transfection with miR194.
To investigate the effect of miR194 on NR1H4 mRNA expression, Caco-2 cells
were seeded in 12-well plates (8×104 and 4×105 cells/ml, respectively). After 24
h, cells were transfected with 100 nM hsa-mirVANA miRNA mimics or anti-miR
miRNA inhibitors (hsa-miR-194-5p and corresponding negative controls, Life
Technologies) by using Lipofectamine RNAiMax diluted in Opti-MEM I (both
purchased from Invitrogen) at a final concentration of 3 mM. Hsa-miR-1 and its
known suppressive effect on twinfilin-1 (TWF-1) expression were used as a
positive control. After 4 h of incubation, the transfection medium was replaced
with fresh complete growth medium. At 48 h after transfection, total mRNA was
isolated by use of TRIzol reagent (Life Technologies). FXR and FGF19 mRNA
were quantified in three independently performed experiments. The effect of
miR194 on NR1H4 mRNA expression in 3D organoids was measured as
previously described with several modifications (123). For mRNA assessment,
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organoids received either 100 nM hsa-mirVANA miRNA mimics/inhibitors or
negative as previously described. miRNA complexes were formed using
RNAiMAX (Invitrogen) in DMEM (Gibco) containing 10% normal/dialyzed FBS
(Gibco). In all conditions antibiotics were omitted as recommended by the
manufacturer to preserve viability during the transfection process. 500 μl of
formed miRNA complex medium was then bathed over 50 μl matrigel contained
within a single well of a 24-well plate overnight and replaced the following
morning with normal organoid medium as mentioned above. At 48 h after
transfection, total mRNA was isolated by use of TRIzol reagent (Life
Technologies). Fxr and Fgf15 mRNA were quantified in three independently
performed experiments.
2.2.21 16S ribosomal RNA (16S rRNA) gene library preparation and sequencing
on the Illumina MiSeq
Fecal pellets were collected into sterile tubes at the end of the experiment and
stored at −80°C. Microbial genomic DNA was extracted from frozen fecal
samples using DNeasy PowerSoil kit (Cat#:12888-100, Qiagen, Germantown,
MD, USA) according to the manufacturer’s instructions. The composition of fecal
microbiota was analyzed using Illumina MiSeq technology targeting the variable
V3 and V4 regions of 16S ribosomal RNA. 16S variable regions were amplified
using 12.5ng microbial genomic DNA. PCR conditions are as follows: 95°C for 3
min; 25 cycles of 95°C for 30s, 55°C for 30s, and then 72°C for 30s; and 72°C for
5 min. The primers used for 16S Amplicon PCR are as follows: Forward: 5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
; Reverse: 5′GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC. Index PCR was performed to attach dual indices and Illumina sequencing
adapters using the Nextera Index Kit (Cat#: FC-121-1012, Illumina, San Diego,
CA, USA). Each step was followed by the PCR clean-up, using AMPure XP
beads to obtain a purified library. After libraries were normalized, pooled, and
denatured, sequencing was done using Illumina MiSeq Reagents kit v3 (600
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cycles, read lengths up to 2 × 300 bp) (Cat#: MS-102-3003, Illumina, San Diego,
CA, USA) on an Illumina MiSeq instrument.
Sequencing data analysis
Quality control of raw sequence files was performed using FastQC and further
analyzed using QIIME 2 (version 2019.04) (124). Briefly, the paired-end files per
sample were merged and imported into a QIIME 2 artifact. The sequences reads
were then demultiplexed and denoised into amplicon sequence variants (ASVs)
using DADA2 in QIIME 2 which can identify more real variants and output fewer
spurious sequences than other methods. The resulted feature table and
representative sequences were used for the downstream analysis. Rarefaction
curve using the observed operational taxonomy unit (OTU) and Shannon index
generated by QIIME 2 were used as metrics of α-diversity (125). Principal
coordinate analysis (PCoA) was performed to compare microbial community
structure between groups (β-diversity), using both weighted and unweighted
UniFrac (126). Heat map analysis of OTU abundance was performed using R
software (https://www.r-project.org/). Linear discriminant analysis (LDA) effect
size (LEfSe) method was used to find the most differentially abundant enriched
microbial taxa between the different diets. The analysis was performed on
Galaxy platform (http:/huttenhower.sph.harvard.edu/galaxy). The data generated
from LEfSe analysis was shown by cladogram and histogram with LDA score > 2
and a significance of α < 0.05, as determined by Wilcoxon rank-sum test (127).
The 16S data set was used for metagenome predictions using the software
package PICRUSt2 (128). Predictions were based on Kyoto Encyclopedia of
Genes and Genomes (KEGG) database pathways (129), and the output was
based on the pathway mapping of the MetaCyc database (130) . A Venn diagram
was used to show genus distribution between groups.
2.2.22 Statistical Analysis
Statistical analyses were performed using the statistical computer package
GraphPad Prism, version 9 (GraphPad Software Inc., San Diego, CA). Results
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are expressed as means ± SEM. Statistical comparisons were made using twoway analysis of variance (ANOVA) with Bonferroni’s post hoc test, one-way
ANOVA with Tukey’s post hoc test, or Student t test, where appropriate.
Differences were considered to be significant at p<0.05. For 16s metagenomics
studies, data were expressed as mean ± SD (standard deviation) and analyzed
using two-way ANOVA to test the factors of copper, fructose, and their
interactions (copper × fructose), followed by Tukey’s multiple comparison test.
The Kruskal-Wallis test was used for pairwise comparison between treatment
groups (α-diversity). Comparison of the mean distance matrix (β-diversity)
between two treatment groups using PERMANOVA (a nonparametric method for
multivariate analysis of variance) with permutation tests was based on UniFrac
distance matrix (999 Monte Carlo permutations). Two-tailed nonparametric
Spearman correlation was done with GraphPad Prism. Differences at p≤ 0.05
were considered to be statistically significant.
Significance is noted as *p<0.05, **p<0.01, ***p<0.001 between groups.
Table 2: Primer sequences used for Real-time PCR studies in mice

Target genes

Sequences

Cyp7a1

Forward

5`- TGGAATAAGGAGAAGGAAAGTA -3`

Reverse

5`- TGTGTCCAAATGCCTTCGCAGA -3`

Forward

5`- TGCCTGGGTCGGAGGAT-3`

Reverse

5`-GAGCCAGGGCAATCTCATACTT -3`

Forward

5`- CCTCTGGACAAGGGTTTTGTG -3`

Reverse

5`- GCACCGTGAAGACATCCCC -3`

Forward

5`- GGAGCCACGACCCTAGATG -3`

Reverse

5`- GCCATGCCAAGATAAGGAAGC-3`

Forward

5`- TGTGAGGGCTGCAAAGGTTT-3`

Reverse

5`- ACATCCCCATCTCTCTGCAC -3`

Forward

5`- GAGGACCAAAACGAACGAAATT -3`

Reverse

5`- ACGTCCTTGATGGCAATCG -3`

Forward

5`-TCTGCAGGTCGTCCGACTAT -3`

Reverse

5`-CAGGCAGTGGCTGTGAGAT -3`

Cyp27a1
Cyp8b1
Cyp7b1
Fxr
Fgf15
Shp
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Oatp4
Mrp2
Mrp3
Mrp4
Ost-α
Ost-β
Asbt
Bsep
18S

Forward

5`-GATCCTTCACTTACCTGTTCAA -3`

Reverse

5`-CCTAAAAACATTCCACTTGCCATA -3`

Forward

5`-GCTTCCCATGGTGATCTCTT -3`

Reverse

5`-ATCATCGCTTCCCAGGTACT -3`

Forward

5`-TGAGATCGTCATTGATGGGC -3`

Reverse

5`-AGCTGAGAGCGCAGGTCG -3`

Forward

5`-TTAGATGGGCCTCTGGTTCT -3`

Reverse

5`-GCCCACAATTCCAACCTTT -3`

Forward

5`-TGTTCCAGGTGCTTGTCATCC-3`

Reverse

5`-CCACTGTTAGCCAAGATGGAGAA -3`

Forward

5`-GATGCGGCTCCTTGGAATTA -3`

Reverse

5`-GGAGGAACATGCTTGTCATGAC -3`

Forward

5`-ACCACTTGCTCCACACTGCTT -3`

Reverse

5`-CGTTCCTGAGTCAACCCACAT -3`

Forward

5`- GCTGCCAAGGATGCTAATGC -3`

Reverse

5`-GGAGGAACATGCTTGTCATGAC -3`

Forward

5`- CTAACCCGTTGAACCCCATT-3`

Reverse

5`- CCATCCAATCGGTAGTAGCG-3`

Table 3: Primer sequences used for Real-time PCR studies in Caco-2 cells
Target genes

Sequences

FGF-19

Forward

5`-AGATCAAGGCAGTCGCTCTG -3`

Reverse

5`- CGGATCTCCTCCTCGAAAGC-3`

Forward

5`-TCAAGTCCATTCCGACCAGC -3`

Reverse

5`- AAGAAGGCCAGCGATGTCAA-3`

Forward

5`- CCAGCAAGAGCACAAGAGGA-3`

Reverse

5`- GAGATTCAGTGTGGTGGGGG-3`

SHP
GAPDH

Table 4: Primer sequences used for Real-time PCR studies in gut microbiota
Target genes

Sequences

Firmicutes

Forward

5`- ATGTGGTTTAATTCGAAGCA -3`

Reverse

5`- AGCTGACGACAACCATGCAC -3`

Forward

5`- CGCGGCCTATCAGCTTGTTG -3`

Lactobacillus
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Bacteroidetes
16S

Reverse

5`- CCGTACTCCCCAGGCGGGG -3`

Forward

5`- GGARCATGTGGTTTAATTCGATGAT-3`

Reverse

5`- AGCTGACGACAACCATGCAG -3`

Forward

5`-ACTCCTACGGGAGGCAGCAGT -3`

Reverse

5`-ATTACCGCGGCTGCTGGC -3`

2.3 Results
2.3.1 LDNP Treatment Reversed Alcohol-induced Fatty Liver and Liver Injury
We first characterized the sizes of nanoparticles produced by LGG as shown in
Fig. 2.3.1A. LDNPs were isolated by ultracentrifugation from bacteria culture
(2 × 109 CFU/mL). We next examined which cells took up LDNPs. We incubated
human colorectal adenocarcinoma Caco-2 cells and mouse hepatocyte Hepa1-6
cells with PKH67-labeled LDNPs. PKH67-positive LDNPs were found mainly in
Caco-2 cells but not hepatocytes (Fig. 2.3.1B). These data suggest that LDNPs
are taken up primarily by the intestine epithelial cells.
We have previously demonstrated that LDNP treatment protected against
alcohol-induced liver injury. We confirmed this protective effect of LDNPs against
ALD in the NIAAA binge-on-chronic mouse model (Fig. 2.3.1C-1G).
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Figure 2.3.1. LDNP treatment reversed alcohol-induced liver injury. (A)
Representative transmission electron microscopy image of LDNPs. (B) Uptake of
LDNPs in human colorectal adenocarcinoma Caco-2 and hepatocytes Hepa1-6
cells. (C) Experimental design of animal treatment. (D) Representative
microphotographs of H&E stained mouse liver sections. (E) Hepatic TG levels.
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(F) Liver-to-body weight ratio. (G) Serum ALT and AST levels.

We further showed that LDNPs’ effect on the reduction of liver fat accumulation
is, at least in part, by inhibiting lipogenesis. Hepatic mRNA levels of Srebp-1c, a
critical transcription factor for de novo lipogenesis was significantly increased by
alcohol but unchanged by LDNP treatment (Fig. 2.3.1H). However, nuclear levels
of Srebp-1c protein were significantly increased by alcohol and inhibited by
LDNP treatment, while cytoplasmic levels of Srebp-1c protein were unchanged
by alcohol or LDNP treatment, indicating an inhibited activation by LDNPs (Fig.
2.3.1I). The Srebp-1c target lipogenesis genes, Acc and Fasn, were markedly
increased by alcohol feeding and decreased by LDNP treatment (Fig. 2.3.1J).
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Figure 2.3.1. LDNP treatment reversed alcohol-induced liver injury. (H) Hepatic
mRNA levels of Srebp-1c. (I) Nuclear and cytoplasmic protein expression of liver
Srebp1c. (J) Liver Acc and Fasn mRNA levels. Data are expressed as
mean ± SEM (n = 5-7 mice/group).
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2.3.2 Alcohol Feeding and LDNP Treatment Altered Hepatic BA Metabolism and
Intestinal FXR-FGF15 Signaling Pathway
To investigate the involvement of BA metabolism in the effects of alcohol and
LDNP treatment, liver and circulating BA levels were determined. Hepatic and
total serum BA levels were significantly increased in AF mice and were markedly
reduced by LDNP treatment (Fig. 2.3.2A-B). Fecal BAs were significantly
increased by alcohol and moderately reduced by LDNP treatment (Fig. 2.3.2C).
In the liver, the relative proportion of lithocholic acid (LCA), which is the most
toxic BA in liver (131), was increased by alcohol and reduced after LDNP
treatment (Fig. 2.3.2D). Serum 12α-Hydroxylated BA, which can induce hepatic
steatosis (132), was significantly upregulated by alcohol and reduced by LDNP
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Figure 2.3.2 LDNP treatment changed BA metabolism through FXR-FGF15
signaling. (A) Liver BA level. (B) Serum BA level. (C) Fecal BA levels. (D)
Hepatic LCA level. (E) Serum 12α-Hydroxylated BA level.
Importantly, alcohol feeding caused a robust elevation of the serum 7α-hydroxy4-cholesten-3-one (C4) level, a surrogate marker of BA synthesis, and this was
significantly reduced by LDNP treatment (Fig. 2.3.2F). Alcohol-fed mice had
elevated hepatic mRNA expression levels of Cyp7a1, the major enzyme in the
classic BA synthesis pathway, which was significantly reduced by LDNP
(Fig. 2.3.2G). The Cyp7a1 protein level was increased in AF mice, and
significantly reduced by LDNP treatment (Fig. 2.3.2H). mRNA levels of additional
P450 enzymes involved in BA synthesis, such as Cyp8b1 and sterol 27hydroxylase (Cyp27a1), were not altered by alcohol exposure or by LDNP
treatment (Fig. 2.3.2I). However, mRNA expression of oxysterol 7α-hydroxylase
(Cyp7b1) was decreased by alcohol and further reduced after LDNP treatment
(Fig. 2.3.2J). These results indicate that LDNP treatment inhibits alcoholincreased BA synthesis, which is likely mediated by a CYP7A1-regulated
mechanism.
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Figure 2.3.2 LDNP treatment changed BA metabolism through FXR-FGF15
signaling. (F) Serum C4 level. (G) Hepatic Cyp7a1 mRNA level. (H) Hepatic
protein expressions of Cyp7a1. (I) Hepatic mRNA expressions of Cyp8b1 and
Cyp27a1. (J) Hepatic mRNA expression of Cyp7b1. (K) Hepatic mRNA
expression of Fxr.
Hepatic mRNA expression of Fxr was not altered by alcohol or LDNP treatment
(Fig. 2.3.2K). However, we found that hepatic levels of chenodeoxycholic acid
(CDCA) and deoxycholic acid (DCA), potent FXR agonists, were significantly
decreased in alcohol-fed mice, but were not altered by LDNP treatment. In
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addition, no changes were found for hepatic cholic acid (CA) (FXR agonist) and
T-α/βMCA (FXR antagonists) concentrations in the liver (Fig. 2.3.2L).
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Figure 2.3.2 LDNP treatment changed BA metabolism through FXR-FGF15
signaling. (K) Hepatic mRNA expression of Fxr. (L) Selected liver BAs. (M)
Hepatic mRNA expression of Shp.
SHP is an orphan receptor and is regulated by FXR and by FGF15 derived from
intestine (133). Alcohol feeding decreased hepatic Shp mRNA expression, which
was markedly increased by LDNP treatment (Fig. 2.3.2M). Recent studies
showed that phosphorylation of SHP increased its nuclear localization and
activation, leading to an active repression of hepatic lipogenesis (25) and BA
metabolism (134, 135). Consistent with previous studies, we showed that
cytosolic Shp levels were increased in alcohol-fed mice, whereas nuclear Shp
levels were substantially reduced by alcohol and increased by LDNP
(Fig. 2.3.2N). Taken together, these data suggest that LDNP treatment
suppressed BA synthesis in alcohol-fed mice through a hepatic SHP-CYP7A1mediated pathway.
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Figure 2.3.2 LDNP treatment changed BA metabolism through FXR-FGF15
signaling. (M) Hepatic mRNA expression of Shp. (N) Nuclear and cytoplasmic
protein expression of liver Shp.
It is known that intestine-derived FGF15 plays a pivotal role in hepatic BA
metabolism by binding to FGF receptor 4 (FGFR4) complexes on hepatocytes
leading to a suppression of BA synthesis (136). To understand the effects of
LDNPs on BA metabolism in ALD, we measured intestinal FXR-FGF15 signaling.
Alcohol feeding caused a significant reduction of circulating Fgf15 protein levels,
which was restored by LDNP treatment (Fig. 2.3.2O). Similarly, mRNA levels
of Fgf15 in ileal tissues were decreased by alcohol exposure and increased by
LDNP treatment (Fig. 2.3.2P). Ileal mRNA and protein levels of Fxr were
significantly reduced by alcohol exposure and normalized by LDNP treatment
(Fig. 2.3.2Q-R). These data suggest that alcohol exposure reduced the ileal
FXR-FGF15 signaling pathway and LDNP treatment normalized it, which could
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contribute to the beneficial effects of LDNPs on the inhibition of BA synthesis in
the liver in ALD.
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Figure 2.3.2 LDNP treatment changed BA metabolism through FXR-FGF15
signaling. (O) Serum Fgf15 levels. (P) Ileum mRNA expression of Fgf15. (Q)
Ileum mRNA expression of Fxr. (R) Hepatic protein expression of Fxr. n = 57/group.
2.3.3 Alcohol Feeding Increased Ileal miR194 Expression
miRNAs are a class of small nucleotide non-coding RNAs and have been
implicated in the regulation of genes involved in ALD (91, 137). To evaluate how
the Fxr gene is regulated at the transcriptional level by miRNAs, we performed a
miRNA microarray assay in ileal samples in PF and AF mice. The array analysis
revealed an important dysregulation of miRNA expression in AF mice compared
with PF mice, with 121 miRNAs increased and 13 miRNAs decreased. In
particular, we observed that alcohol feeding markedly upregulated miR194 and
miR192 (Fig. 2.3.3A), which belong to same cluster, and suppress Fxr gene
expression by binding 3′-UTR of Nr1h4 gene (Fxr), as revealed by bioinformatics
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analysis (48, 138). We further confirmed the ileal upregulation of miR194 and
miR192 by real-time qPCR (Fig. 2.3.3B). Notably, alcohol exposure significantly
increased miR192 levels, but did not change the hepatic levels of miR194 (Fig.
2.3.3C), implying the action of alcohol consumption on miR194 regulation is likely
intestine-specific. Recent studies showed that extracellular miRNAs are
packaged inside exosomes in cell lines or in healthy human plasma, and serum
exosomal miR192 is a biomarker of ALD (91). Consistent with previous studies
(91), we found that alcohol feeding increased serum exosomal miR192, but not
miR194 levels (Fig. 2.3.3D), further suggesting a local regulation of ileal miR194
by alcohol. We further found that the expression of both pri-miR194-2 and primiT194-1 in the ileum were increased by alcohol feeding, but the increase of primiR194-2 was more pronounced (Fig. 2.3.3E). Previous study showed that primiR194-2 is the major contributor to the expression of miR194 in the
gastrointestinal tract (139). These results suggest a partially transcriptional
regulation of miR194 expression in the intestine by alcohol.
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Figure 2.3.3. The effects of alcohol and LDNPs on intestinal microRNA
expression and validation of miR194 binding on FXR. (A) Heat map of the most
changed miRNAs by a microRNA array assay and Volcano plot of ileal miRNA in
AF mice compared with PF mice by a microRNA array analysis. (B) Validation of
two dysregulated miRNAs (miR194 and miR192) in ileum samples by RT-q-PCR.
(C) Hepatic miR194 (left panel) and miR192 (right panel) expression. (D) Serum
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exosomal levels of miR194 (left panel) and miR192 (right panel). (E) Ileum PrimiR194-1/2 mRNA expression.

Interestingly, intestinal mucus-derived exosomes contain miR194, and it was
significantly increased by alcohol feeding (Fig. 2.3.3F). However, the cryptderived exosomal miR194 was unchanged (Fig. 2.3.3G), indicating that alcohol
upregulates miR194 in the intestinal epithelium. Importantly, LDNP treatment
significantly reduced the alcohol-upregulated mature miR194 and pri-miR194-2 in
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Figure 2.3.3. The effects of alcohol and LDNPs on intestinal microRNA
expression and validation of miR194 binding on FXR. (F) Mucus exosomal
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miR194 (left panel) and Pri-miR194-2 (right panel) expressions.
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miRNAs are normal constituents of murine and human feces, and most fecal
miRNAs are derived from host gut epithelial cells (140). Fecal miRNAs have
been used as biomarkers for screening and diagnosis of multiple intestinal
diseases (141). Thus, we performed a miRNA microarray assay of fecal samples
from PF and AF mice. As shown in Fig. 2.3.3I, alcohol feeding induced a
significant dysregulation of fecal miRNA expression compared with PF mice.
Similarly, the fecal miR194 level was also significantly elevated by alcohol (Fig.
2.3.3J). These data unambiguously demonstrate that alcohol exposure increases
intestinal epithelium-derived miR194 expression, which is suppressed by LDNP
treatment.

50

I

miR194

Fecal miR194
(Fold Change)

J

10

**

**

8
6
4
2

PF
PF
+ A
A LD F
F+ N
LD P
N
P

0
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To further investigate the effect of miR194 on FXR expression, human intestinal
epithelial Caco-2 cells were transfected with 100 nM miR194 mimic for 24 hours.
As shown in Fig. 2.3.3K, FXR mRNA levels were suppressed by miR194 mimic.
Moreover, the mRNA levels of FXR- target gene, FGF19, were also reduced by
miR194 mimic (Fig. 2.3.3K).
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Figure 2.3.3. The effects of alcohol and LDNPs on intestinal microRNA
expression and validation of miR194 binding on FXR. (K) miR194 mimic on FXR
and FGF19 expressions in Caco-2 cells.

Next, we examined the effect of miR194 on Fxr expression in mouse 3D
intestinal organoids. We generated 3D self-organizing enteroid cultures in vitro,
which recapitulated features of the in vivo small intestinal epithelium, including
the formation of an internal lumen and distinct crypt- and villus-like domains (142)
(Fig. 2.3.3L). The organoid culture was transfected with 100 nM miR194 mimic or
anti-miR194 inhibitor for 48 hours. miR194 mimic reduced, and miR194 inhibitor
increased intestinal Fxr mRNA and protein levels (Fig. 2.3.3M). Similar results
were obtained for Fgf15 mRNA and serum Fgf15 proteins (Fig. 2.3.3N). These
data demonstrate that miR194 suppresses FXR gene expression in the intestinal
tissue.
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Figure 2.3.3. The effects of alcohol and LDNPs on intestinal microRNA
expression and validation of miR194 binding on FXR. (L) Organoid culture of
isolated mouse small intestinal epithelium in Matrigel matrix and ENR media
(conventionally differentiated) for 14 days. Isolated crypts form 3D cysts which
bud after 7 days of culture to form crypt-and villus-like domains. (M) miR194
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expressions in mouse intestinal organoids. (N) miR194 mimic and inhibitor on
FGF15 mRNA (left panel) and protein (right panel) expressions in intestinal
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In addition, EtOH or LDNPs had no direct effects on the expression levels of
miR194, FXR and FGF15 in Caco-2 cells (Fig. 2.3.3O-Q), indicating that the
effects of alcohol and LDNPs observed in vivo may be regulated indirectly
through mediators such as the modification of microbiota.
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Figure 2.3.3. The effects of alcohol and LDNPs on intestinal microRNA
expression and validation of miR194 binding on FXR. (O) Relative FXR, FGF19
and miR194 mRNA expressions in Caco-2 cells treated with different dose of
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EtOH for 24 hours. (P) FXR mRNA (left panel) and protein (right panel) levels in
Caco-2 cells treated with LDNP for 24 hours. (Q) Relative mRNA expressions
of FGF19 (left panel) and miR194 (right panel) in Caco-2 cells treated with LDNP
for 24 hours. iMAX: lipofectamine RNAiMAX. Data are expressed as
mean ± SEM. n = 3-5/group.
2.3.4 Alcohol Feeding Decreased Fecal Taurine Concentrations and TUG1
Expression.
Previous studies (143) demonstrated that miR194 was regulated by taurineupregulated gene 1 (TUG1), a long non-coding RNA, which is upregulated by
taurine. TUG1 induced an epigenetic regulator that enhances zeste homolog 2
(EZH2)-associated promoter methylation, which decreases the cellular
concentration of miR194 (144). In addition, higher levels of TUG1 can directly
bind to and act as a biological sponge to reduce miR194 expression (144). Our
results showed that ileal TUG1 expression was significantly decreased by alcohol
and increased after LDNP administration (Fig. 2.3.4A). Similarly, fecal taurine
concentrations were also reduced by alcohol feeding and restored by LDNP
treatment (Fig. 2.3.4B). The reduction of fecal taurine concentration by alcohol
feeding was also demonstrated in other alcohol feeding models (145). Notably,
taurine treatment increased TUG1 expression and reduced miR194 levels in
mouse 3D intestinal organoids (Fig. 2.3.4C). Moreover, taurine pre-treatment
restored ileum TUG1 and suppressed miR194 levels in alcohol-fed mice (Fig.
2.3.4D).
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Figure 2.3.4. Alcohol Feeding Increased miR194 Expression though TaurineTUG1 pathway. (A) Ileum TUG1 mRNA levels. (B) Fecal taurine concentration.
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under taurine treatment.
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Free taurine is released from tauro-BA by gut bacteria and choloylglycine
hydrolase (bile salt hydrolase, BSH, classified as EC 3.5.1.24) is responsible for
the deconjugation (deamidation) of conjugated (amidated) BAs (Fig. 2.3.4E). Of
note, deltaproteobacteria convert sulfonated taurine (2-aminoethanesulfonate) to
ammonia, acetate, and sulfite via taurine-pyruvate aminotransferase
(EC 2.6.1.77, encoded by TPA). Previous studies have identified that B.
wadsworthia uses taurine as a substrate (146). Therefore, alcohol feeding
caused-gut bacterial dysbiosis may contribute to the taurine regulation of
intestinal miR194.

E

Figure 2.3.4. Alcohol Feeding Increased miR194 Expression though TaurineTUG1 pathway. (E) Conjugated bile acid metabolism in intestine.

To evaluate gut microbiota alteration, we performed 16s metagenomics analysis
of fecal samples from mice. Fig. 2.3.4F is a snapshot for the α-rarefaction curves
for the number of observed OTUs indicating that PF group has the highest
number of observed OTUs while AF group has the smallest number of observed
OTUs. LDNP treatment did not restore the loss of α-diversity by alcohol feeding.
Principal covariant analysis (PCoA) showed that the mean distance between PF,
AF and AF+LDNP were significantly different (p < 0.05) (Fig. 2.3.4G). At the
phylum level, alcohol feeding led to a remarkable increase in the abundance of
Proteobacteria and Firmicutes and a decrease in Bacteroidetes and
Verrucomicrobia. Interestingly, Akkermansia muciniphila, a Gram-negative
intestinal commensal belonging to Verrucomicrobia phylum, has been shown to
promote barrier function partly by enhancing mucus production
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(147). Importantly, LDNP treatment prevented the alcohol-induced expansion of
the Proteobacteria and the alcohol-decreased Verrucomicrobia (Fig. 2.3.4H).
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H

Figure 2.3.4. Alcohol Feeding Increased miR194 Expression though TaurineTUG1 pathway. (F) The alpha rarefaction curves for the number of observed
OTUs. (G) The matrix for the Bray-Curtis (upper panel) and comparison of the
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mean distance between two condition groups (lower panel). (H) Taxonomic
composition of the gut microbiota.
Importantly, our results showed that bacterial genomic DNA encoding BSH was
significantly reduced by alcohol feeding but not altered after LDNP treatment
(Fig. 2.3.4I, left panel). To determine the functional changes of the intestinal
microbiota related to BA de-conjugation, an enzymatic assay of BSH activity was
performed in fecal samples. Results showed that BSH activity was markedly
reduced after alcohol feeding and significantly increased by LDNP treatment (Fig.
2.3.4I, right panel). Gut microbiota analysis revealed that genus levels of
Streptococcus, a major BSH containing bacterium, and Lactobacillus, the welldefined BSH-containing bacterial genus (148), were significantly decreased by
alcohol, and increased after LDNP treatment (Fig. 2.3.4J). Additionally, the
bacterial genomic DNA encoding TPA was increased by alcohol feeding and
decreased by LDNP, although without statistical significance (Fig. 2.3.4K, left
panel). However, taurine-consume bacteria species-B. wadsworthia, was
significantly increased by alcohol and reduced by LDNP treatment (Fig. 2.3.4K,
right panel).
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Figure 2.3.4. Alcohol Feeding Increased miR194 Expression though TaurineTUG1 pathway. (I) OTUs of BSH (left panel) and fecal BSH activity (right panel).
(J) Lactobacillus and Streptococcus levels. (K) OTUs of TPA (left panel) and
fecal B. wadsworthia change (right panel). Mice were treated as described in the
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Fig 1, and taurine was added to the drinking water or diet at a dose of 2g/kg
bw/mouse for total 25 days. n = 3-8/group.

Taken together, these results suggest that alcohol feeding causes intestinal
dysbiosis that decreases gut taurine concentration, which in turn, results in a
reduced TUG1 expression and consequently an increased miR194 expression,
and this dysregulation can be reversed by LDNP treatment.
2.3.5 Alcohol Feeding Altered BA Profile and FXR Activity
Liver-derived BAs flow into the intestine from the gallbladder and undergo deconjugation and detoxification by gut bacteria. Conjugated and deconjugated
BAs often possess different FXR agonism activities (149-152). We further
performed metabolomic BA profiling in the fecal and serum samples. As shown in
Fig. 2.3.5A, isodeoxycholic acid (iso-DCA, * labeled), a BA that is formed via
epimerization of DCA by intestinal bacteria and inhibits FXR activity (153), was
the major form of BA in feces. Iso-DCA levels were increased in AF mice and
reduced by LDNP treatment. Similarly, LCA (^ labeled), the most toxic BA (131),
was also increased by alcohol feeding. ω-muricholic acid (ω-MCA, ^^ labeled),
which is the second most abundant form of BA in the feces and acts as an FXR
agonist in intestine (154), was decreased by alcohol feeding. 12-ketolithocholic
acid and cholic acid-7-sulfate (CA7S) were also decreased by alcohol feeding.
Importantly, LDNP treatment had minimal effect on the BA profile in PF mice, but
markedly reversed the changes in AF mice.
Fecal total BAs profiling was also shown in Fig. 2.3.5A. Interestingly, the tauroBA/total BA ratio was slightly increased by alcohol and decreased by LDNP
treatment (Fig. 2.3.5B). Previous research showed that tauro-BA down-regulated
intestinal FXR-FGF15 signaling (155). Next, we analyzed the selected BAs that
reportedly have FXR ligand activity. Fecal levels of CA and DCA were
significantly decreased in alcohol-fed mice, and this effect was reversed by
LDNPs. Alcohol feeding increased, and LDNPs decreased, LCA levels. There
was no significant effect on fecal CDCA and T-α/βMCA levels by either alcohol or
LDNP treatment (Fig. 2.3.5C).
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Figure 2.3.5. Effects of alcohol and LDNP on FXR activity. (A) Fecal bile acid
composition ratios and fecal BA classes of mice. (B) Fecal tauro-BA/total BA
ratios. (C) Selected fecal BA concentrations.
Most gut microbiota-manipulated BAs are reabsorbed by the intestine into the
circulation. We thus measured the serum BA profile. In contrast to fecal BAs, the
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major forms of BAs in the serum were DCA and CDCA. TCA levels were low in
PF mice but dramatically increased by alcohol-feeding and decreased by LDNPs
(Fig. 2.3.5D, * labeled). Tauro-BA accounted for about 20% of the total BA in the
serum of PF mice and that was increased to 40% by alcohol feeding. LDNP
treatment significantly reduced the tauro-BA/total BA ratio in both PF and AF
mice (Fig. 2.3.5E). Alcohol-increased tauro-BAs may contribute to the decrease
in free taurine, as demonstrated previously (Fig. 2.3.4B).
Serum total BA levels were significantly increased by alcohol and decreased by
LDNPs (Fig. 2.3.2B). This was mainly due to the changes in conjugated BAs,
since the unconjugated BA level was insignificantly altered by either alcohol or
LDNPs (Fig. 2.3.5F). Interestingly, serum FXR agonists, DCA and CDCA, were
reduced by alcohol feeding and restored by LDNP treatment. The levels of CA,
another FXR agonist, were low and not altered by alcohol or LDNP treatment.
Interestingly, T-α/βMCA, FXR antagonist, was increased by alcohol feeding but
markedly reduced by LDNP treatment (Fig. 2.3.5G).
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Figure 2.3.5. Effects of alcohol and LDNP on FXR activity. (D) Serum BA
composition ratios. (E) Serum tauro-BA/total BA ratios. (F) Serum BA classes
and BA profile of mice. (G) Selected serum BA concentrations.
To further determine FXR activity, we transfected HEK293 cells with an FXR
expressing plasmid and an FXR luciferase reporter plasmid. The cells were
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treated with fecal supernatants or serum samples, and FXR agonist CDCA was
used as a positive control. As expected, CDCA treatment markedly increased
FXR activity. Serum (Fig. 2.3.5H, left panel) and fecal supernatants (Fig. 2.3.5H,
right panel) from PF mice also had significantly increased FXR-luciferase activity,
which was markedly reduced in alcohol feeding samples. Importantly, LDNP
treatment improved the alcohol-suppressed FXR-luciferase activity (Fig. 2.3.5H).
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Figure 2.3.5. Effects of alcohol and LDNP on FXR activity. (H) Luciferase
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with FXR expression plasmid, FXR reporter plasmid, and β-galactosidase
expression plasmid. Cells were stimulated with CDCA (20 μM) alone, fecal
supernatant or serum for 6 hours. n = 3-5/group.
Taken together, in addition to the transcriptional regulation, alcohol feeding
caused dysregulation of BAs that reduced FXR activation, and LDNP treatment
positively modified gut microbiota and BA metabolism that led to an increased
FXR activity in ALD mice.
2.3.6 Intestinal FXR Deficiency Abolished the Protective Effect of LDNP against
Alcohol-induced Liver Injury
Our results demonstrated that LDNPs increased intestinal FXR activity in alcoholfed mice. We thus hypothesized that the lack of intestinal FXR would diminish the
protective effects of LDNPs. To test this hypothesis, we used intestinal epithelial
cell-specific Fxr knockout mice (Fxr∆IEC). Fxr∆IEC and Fxrfl/fl mice were fed Lieber
DeCarli liquid diet in a binge-on-chronic alcohol feeding model as described in
Fig 1 and LDNPs were given to the mice once daily for the last three days.
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Agreeing with previous studies (156), alcohol feeding increased hepatic fat
accumulation and liver injury in the Fxr∆IEC mice compared to Fxrfl/fl mice (not
shown). Importantly, the beneficial effects of LDNP treatment on alcohol-induced
fatty liver and liver injury were diminished in the Fxr∆IEC mice (Fig. 2.3.6A-C).
LDNP treatment was no longer effective on the reduction of BA levels in the
serum and liver in the Fxr∆IEC mice (Fig. 2.3.6D). Liver Cyp7a1 mRNA and protein
levels were also unchanged by LDNPs (Fig. 2.3.6E-F). Taken together, these
data indicate that intestinal FXR plays a major role in the beneficial effects of
LDNP on alcohol-induced liver injury.
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Figure 2.3.6. The beneficial effect of LDNPs was abolished in Fxr∆IEC mice. (A)
Representative microphotographs of H&E-stained mouse liver sections. (B)
Hepatic TG levels. (C) Serum ALT and AST levels. (D) Serum and liver BA
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levels. (E) Hepatic mRNA expressions of Cyp7a1. (F) Hepatic protein levels of
Cyp7a1. n = 3-5/group.
2.3.7 Protective Effect of LDNPs Against Alcohol-Induced Liver Injury was
Diminished in Fgf15 KO Mice
We further examined the effects of LDNPs in FXR-FGF15 pathways in Fgf15-/mice. FGF15 is an endocrine hormone mainly expressed in the intestine in mice,
while human FGF19 is expressed in both intestine and liver under disease
conditions (157, 158). Thus, using whole-body knockout of Fgf15 is appropriate
to dissect the role of Fgf15 in liver pathology in mice. The Fgf15-/- mice were
subjected to the NIAAA binge-on-chronic alcohol model and LDNPs were given
as described previously. Notably, the protective effects of LDNPs against
alcohol-induced liver steatosis and injury in WT control mice were completely
abolished in the Fgf15-/- mice (Fig. 2.3.7A-C). The beneficial effects of LDNPs on
BA reduction in the serum and liver were also diminished in the Fgf15-/- mice (Fig.
7D). Liver Cyp7a1 mRNA and protein levels were increased by alcohol but
unchanged by LDNPs in the Fgf15-/- mice (Fig. 2.3.7E-F). Taken together, those
data indicate that intestinal FXR-FGF15 signaling is required for the beneficial
effects of LDNPs against alcohol-induced liver injury.
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levels. (E) Hepatic mRNA expressions of Cyp7a1. (F) Hepatic protein levels of
Cyp7a1. n = 3-5/group.
2.3.8 Patients with Alcohol-Associated Hepatitis had Elevated Fecal Bile Acids
and miR194 but Decreased Taurine Levels and BSH Activity
We further examined the miR194-FXR signaling in samples from patients with
AH. Agreeing with previous studies (11, 116), serum BA concentrations in AH
patients were significantly higher than in healthy controls (not shown). Fecal
levels of total BAs were also significantly increased in AH patients (Fig. 2.3.8A).
Importantly, fecal miR194 level was elevated in AH patients compared to healthy
controls (Fig. 2.3.8B). Previous research demonstrated a gut dysbiosis in the AH
patients (159) and experimental ALD in mice (51). We further showed fecal
taurine concentration was lower in AH patients compared to healthy controls (Fig.
2.3.8C), and it negatively correlated with AST level (Fig. 8D). Additionally,
patients’ fecal BSH activity is also significantly decreased and negatively
correlated with serum AST level (Fig. 2.3.8E-F). The dysregulated taurine
homeostasis may be a result of decreased BSH-harboring bacteria, such as
Lactobacillus, which contributes to the FXR activation.
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2.4 DISCUSSION
Cholestasis and clinical jaundice may be seen in all stages of ALD, and the
accumulation of toxic BAs is the major contributor (160). Reducing hepatic BA
overload is a therapeutic goal for the management of ALD (161). Clinical studies
demonstrated that patients with AH have an increased BA synthesis even in the
face of cholestasis and increased BA levels (15). BA synthesis is regulated by
hepatic and intestinal FXR signaling. Although it is well-known that BAs are the
endogenous ligands of FXR, how intestinal FXR is regulated at the transcriptional
level in ALD is unknown. In this study we showed that intestinal miR194
suppressed intestinal Fxr mRNA expression in alcohol-fed mice. Alcohol feeding
increased intestinal miR194 and decreased intestinal Fxr expression which led to
a decreased FXR-FGF15 signaling in the enterohepatic axis. We confirmed that
miR194 suppressed FXR gene expression in an intestinal epithelial Caco-2 cell
line and a mouse intestinal organoid culture, and we showed that miR194 mimic
inhibited, whereas miR194 inhibitor increased, FXR mRNA expression. In line
with previous studies (11, 116), we found that alcohol feeding significantly
changed BA profiles in both feces and serum samples. Both fecal and serum
BAs that have potential FXR antagonistic activity were increased, while those
BAs that activate FXR were decreased by alcohol feeding. The combinatorial
effects of alcohol-induced transcriptional suppression and BA-mediated inhibition
of FXR contribute to the defective enterohepatic FXR-FGF15 signaling that is
critical in the regulation of hepatic BA homeostasis and lipogenesis in ALD.
How is intestinal miR194 regulated in mice with experimental ALD? Previous
study showed that alcohol exposure suppressed miR122 in intestinal epithelial
cells leading to a reduced occludin expression and gut leakiness (86). However,
alcohol at physiological concentrations had no effect on miR194 expression in
ileal organoids indicating an indirect regulation that likely involved gut microbiota.
We demonstrated that alcohol consumption-caused gut dysbiosis decreased gut
taurine concentration through decreased deconjugation of tauro-BA by BSHcontaining bacteria and increased taurine-consuming B. wadsworthia. The
reduced taurine levels consequently caused a reduction of TUG1 expression
resulting in the upregulation of miR194. This taurine-depended regulation of
miR194 is further demonstrated in ileal organoids and in mice, in which taurine
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supplementation increased TUG1 expression and decreased miR194
expression. We further demonstrated that fecal taurine concentrations, along with
miR194, were reduced in AH patients and were negatively correlated with serum
AST levels. Previous studies have demonstrated that taurine supplementation
reduced experimental ALD in mice through adipose adiponectin regulation (162).
Our study provided further mechanistic insights into the preventive role of taurine
in experimental ALD. Interfering gut microbiota to increase intestinal taurine
availability suppressing miR194-mediated reduction of FXR-FGF15 signaling is a
plausible strategy for inhibition of ALD development and progression.
Management of ALD is challenging. Previous studies demonstrated that the
administration of probiotics to animals (96) or humans with ALD were beneficial
(50, 119). Probiotic treatment restricted the growth of harmful bacteria, prevented
gut leakiness and attenuated liver injury (50). Our recent studies further showed
that the supernatant from the probiotic, LGG, was effective in the prevention of
ALD in animal models (98, 163). We further showed that the effect of the
supernatant was mediated by probiotic-derived nanoparticles (LDNPs) through
intestinal AhR-IL22 pathway (114). However, this mechanism cannot explain why
LDNP treatment reduced hepatic BA levels in ALD mice. In this study, we
demonstrate that LDNP administration suppresses the alcohol-induced intestinal
miR194 expression and BA dysregulation, and subsequently increases intestinal
FXR-FGF15 signaling and suppresses BA synthesis.
In addition to Fxr transcriptional regulation, it is clear that gut microbiota changes
by alcohol and LDNPs play a critical role in the BA transformation that regulates
FXR ligand activity. Interestingly, tauro-BAs, in particular T-α/βMCA, a significant
FXR antagonist, was increased by alcohol and decreased by LDNPs in serum.
Of note, a previous study showed that chronic alcohol feeding decreased tauroBAs (27). The discrepancy may be a result of different alcohol feeding models. In
addition, it is unknown how FXR activity was changed in above-mentioned study
(27). Different BA species and abundance have profound impact on FXR
activation. Importantly, the alteration of FXR activities by alcohol and LDNP
treatment was confirmed by FXR reporter assay in serum and fecal supernatant
samples. The regulation of intestinal miR194-mediated FXR-FGF15 signaling by
LDNPs causes a reduction of BA de novo synthesis, as shown by the reduction
73

of hepatic Cyp7a1 enzyme and serum C4 levels. Gut-derived FGF15 binds
hepatic FGFR4 and starts a signaling cascade resulting in a phosphorylation of
SHP that promotes its nuclear translocation and subsequent activation. The
regulation of SHP activation not only inhibits Cyp7a1 to suppress BA de novo
synthesis but also inhibits lipogenesis resulting in a reduction of fatty liver. We
further demonstrate that the inhibitory effects of LDNPs on fatty liver and BA
accumulation in mice with ALD require intestinal FXR and FGF15. Intestinal
epithelial FXR knockout and FGF15 depletion abolished the beneficial effects of
LDNPs.
As with most studies, the present study has some limitations. We used 10D+1B
mouse model. Human ALD has a broad spectrum, and various animal models
recapitulate different stages of human ALD, although animal models that mimic
severe ALD are still lacking. The results in the present study need to be
evaluated in different models of ALD. Second, the reduction of intestinal FXR and
FGF15 and elevation of miR194 by alcohol needs to be validated in intestinal
specimens from patients with ALD.
In conclusion, the current study provides a novel mechanism by which intestinal
miR194 regulates FXR activation in ALD, and LDNP treatment inhibits ALD
through intestinal miR194-FXR-FGF15 signaling pathway (Fig. 2.3.9). We
demonstrate that alcohol consumption causes gut dysbiosis that leads to a
reduced gut taurine concentration, and consequently a decreased TUG1
expression and an increased miR194 expression. Increases intestinal miR194
leads to reduced FXR transcription and dysregulated BA profiles that, in turn,
lead to decreased FXR ligand activation, which reduces intestinal FGF15
expression. This defective enterohepatic FXR-FGF15 signaling results in an
increased hepatic BA synthesis and lipogenesis and liver injury. LDNP treatment
increased intestinal FXR activation by suppressing miR194 through gut
microbiota-mediated taurine regulation that leads to the inhibition of alcoholinduced hepatic de novo lipogenesis and BA synthesis and liver injury. Of note,
we administrated LDNPs only in the last three days of our model, suggesting a
treatment potential of LDNP in ALD and other BA-associated liver diseases.
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Fig. 2.3.9 A proposed model of LDNPs prevention against ALD
through modulation of intestinal miR194-FXR-FGF15 signaling.
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CHAPTER 3
TRANSCRIPTION ANALYSIS IDENTIFIES GENES RESPONSIVE FOR
ALCOHOL AND LGG-DERIVED EXOSOME-LIKE NANOPARTICLE
TREATMENT IN THE LIVER AND INTESTINE IN MICE
3.1 Introduction
Probiotics have been used safely as a food supplement for over 100 years. In the
last decade, there has been increasing interest in using probiotics to prevent or
treat specific diseases in experimental animals and humans (164). Multiple
clinical trials have been conducted to investigate the effects of probiotics in the
management of disease states, such as gastrointestinal disorders (165) and
metabolic liver diseases (166). However, the results of these clinical trials are
mixed, likely for multiple reasons. It is clear that viable probiotics must colonize
the gut to exert their function. Host factors, including baseline microbiota, may
cause “colonization resistance” to exclude the potential invading probiotics (167).
The compositional patterns of baseline microbiota may not respond well to
incoming probiotic bacteria (168). In addition, the patient’s underlying medical
condition may negatively affect the ability of the probiotic to survive and colonize
the gut; in particular, conditions such as an immunocompromised state and/or
consumption of medications such as antibiotics are problematic. In addition,
safety outcomes of probiotics in disease management are inconsistent (169).
Recently, we demonstrated that the culture supernatant of a well-characterized
probiotic strain, Lactobacillus rhamnosus GG (LGG), was effective in the
treatment of both experimental alcohol- associated liver disease (ALD) (86) and
nonalcoholic liver disease (163) indicating the benefits of the LGG fermentation
products. However, the mechanisms of action of the LGG supernatant (LGGs)
are yet to be defined.
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Soluble proteins produced by LGG have been shown to regulate intestinal
epithelial cell survival and growth (106) and molecules produced by LGG with
different effects on the host have been described (107, 108). How these
individual products are released from bacteria and interact with the host
cells/bacteria is not clear. Bacteria, along with mammalian cells, release
exosome-like nanoparticles (ELNPs), which are implicated in bacterial cell–cell
interactions and bacterial cell–host cell communications (109). ELNPs carry a
variety of genetic materials (miRNA, mRNA, and other noncoding RNAs),
proteins, and metabolites (110). Recent studies suggest that ELNPs function as
natural effectors of signaling between cells Gram-negative bacteria can produce
ELNPs, and that Gram-positive bacteria are not able to produce ELNPs due to
their thick cell wall. However, recent studies showed that Gram-positive bacteria
can also release ELNPs (111, 112). It has been shown that Lactobacillus-derived
ELNPs have multiple functions, including stimulating the host nervous system,
inducing hepatic cancer cell death, and enhancing the immune response against
pathogenic bacteria (111, 113). We have already shown that nanoparticles
released from LGG (LGG-derived exosome-like nanoparticles, LDNPs) contribute
to the protective effects of LGG against experimental ALD (114). The effects of
LDNPs are mediated through the delivery of the specific cargo material to
intestinal cells to protect barrier integrity. LDNP treatment increases the
expression of antimicrobial peptides (Reg3β and Reg3γ) and intestinal tight
junction proteins in cultured intestinal epithelial cells and in intestinal tissue of
mice fed alcohol. We further showed that the LDNPs were enriched in bacterial
tryptophan metabolites, indole derivatives, which are endogenous aryl
hydrocarbon receptor (AhR) agonists. We also showed that LDNPs protected
against experimental ALD through intestinal AhR-IL22-Reg3-related and nuclear
factor erythroid 2-related factor 2 (Nrf2)–mediated signaling pathways, leading to
reduced bacterial translocation and lipopolysaccharide (LPS) release. The study
in CHAPTER 1 demonstrated that alcohol feeding increases intestinal miR194
resulting in suppressed Fxr gene expression and decreased BA-mediated FXR
activation, which leads to BA accumulation and injury in the liver, and this can be
inhibited by LDNP treatment.
Despite those results, more studies are needed to determine the overall benefits
and mechanisms of LDNPs in ALD. To our knowledge, no study has explored the
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global gene expression patterns in ALD under probiotic treatment. Using the
power of next-generation RNA sequencing (RNA-seq), we provided an
overarching comparative analysis of differentially-regulated genes among three
groups (PF, AF and AF+LDNP) in mouse liver and ileum respectively.
Furthermore, we identified both unique and shared molecular mechanisms and
signaling pathways for LDNP on treatment of ALD.
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3.2 Materials and Methods
3.2.1 Detailed process of animal study, RT-PCR, histological analysis and western
blotting have been described in Chapter 2.
3.2.2 RNA sequencing and analysis
RNA samples were prepared according to library kit manufacturer’s protocol,
indexed, pooled, and sequenced on an Illumina NovoSeq sequencer. In brief,
total RNA integrity was determined using Agilent 4200 Tape Station. Library
preparation was performed with 500ng to 1ug of total RNA. Ribosomal RNA was
blocked using FastSelect reagents (Qiagen) during cDNA synthesis. RNA was
fragmented in reverse transcriptase buffer with FastSelect reagent. mRNA was
reverse transcribed to yield cDNA using SuperScript III RT enzyme (Life
Technologies, per manufacturer's instructions) and random hexamers. A second
strand reaction was performed to yield ds-cDNA. cDNA was blunt ended, had an
A base added to the 3' ends, and then had Illumina sequencing adapters ligated
to the ends. Ligated fragments were then amplified for 15 cycles using primers
incorporating unique dual index tags. Fragments were sequenced on an Illumina
NovaSeq-6000 using paired end reads extending 150 bases. Basecalls and
demultiplexing were performed with Illumina’s bcl2fastq software and a custom
python demultiplexing program with a maximum of one mismatch in the indexing
read. The resulting RNA-seq reads were then aligned to the Ensembl release 76
primary assembly with STAR version 2.5.1a (170). Gene counts were derived
from the number of uniquely aligned unambiguous reads by
Subread:featureCount version 1.4.6-p5 (171). Sequencing performance was
assessed for the total number of aligned reads, total number of uniquely aligned
reads, and features detected. The ribosomal fraction, known junction saturation,
and read distribution over known gene models were quantified with RSeQC
version 2.6.2 (172).
3.2.3 Differential gene expression analysis
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All gene counts were imported into the R package EdgeR (173) and trimmed
mean of M values (TMM) normalization size factors were calculated to adjust
samples for differences in library size. Ribosomal genes and genes not
expressed at a level greater than or equal to 1 count per million reads in the
smallest group size were excluded from further analysis, resulting in 20295
(ileum) and 15399 (liver) genes for downstream analysis. By using the R
package limma (174) weighted likelihoods based on the observed mean-variance
relationship of every gene and sample were calculated for all samples with the
voomWithQualityWeights (175), followed by differential expression analysis
between sample groups. Differentially expressed genes (DEGs) were defined as
those with at least 2-fold difference between two individual groups at multiple test
correction adjusted P <0.05 by Benjamini-Hochberg false-discovery rate (FDR)
method (176). In subsequent biological enrichment analysis, these DEGs were
filtered to keep only those protein-coding genes in the analysis.
3.2.4 Biological enrichment analysis by the Metascape
In present study, gene lists derived from differential expression analyses were
input into an online pathway analysis tool, Metascape, which is a web-based
portal designed to facilitate gene list annotation and analysis from OMICs data
sets to biological insights (177). Metascape utilizes the well-adopted
hypergeometric test and Benjamini-Hochberg p-value correction algorithm to
identify statistically enriched ontology terms. It also uses Kappa similarities to
absorb most redundancies into representative clusters to eliminate confounding
data interpretation issues that can arise from the reporting of multiple ontologies.
Meta-analysis of multiple gene lists identifies commonly enriched and selectively
enriched pathways across multiple data sets. To infer biologically more
interpretable results, Metascape applies a mature complex identification
algorithm called MCODE (178) to automatically extract protein complexes
embedded in the large network that were derived from genes enriched in
biological processes and pathways. Metascape also maps significant gene lists
onto a transcription factor database “Transcriptional Regulatory Relationships
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Unraveled by Sentence-based Text mining” (TRRUST) to help interpret potential
gene regulations (179).

3.3 Results
3.3.1 Alcohol and LDNP Treatments Result in Differential Gene Expression in
Liver and Intestine.
To determine the effect of binge-on-chronic alcohol feeding and LDNP treatment
on hepatic and intestinal gene expression, we performed RNA-seq analysis.
Male C57BL/6J mice were subjected to NIAAA binge-on-chronic EtOH feeding
(Alcohol-Fed, AF), and control mice were fed energy matched maltose dextrin
(Pair-fed, PF). One group of AF mice was gavaged with LDNP once a day in last
three days of alcohol feeding. As shown in Figure 3.3.1, the volcano plots
indicated wide-range differential expression changes between treatment groups,
with robust statistical significance caused by alcohol feeding and by LDNP
treatment in the ileum and liver of study mice. The Venn diagram showed that
alcohol feeding upregulated 4990 protein-coding genes (of which 2934 were 4fold upregulated) and downregulated 1800 protein-coding genes (subsequently
mentioned DEG genes were all referred as to “protein-coding” gene biotype) in
the ileum. LDNP treatment upregulated 497 genes, and down regulated 1886
genes. The gene overlaps showed that 494 downregulated and 1317
upregulated genes by alcohol feeding were oppositely altered by LDNP treatment
(Figure 3.3.1A). In the liver, there were 835 genes differentially expressed (184
down and 651 up) by alcohol feeding, and LDNP treatment increased 115 genes
and decreased 324 genes. With LDNP treatment, 260 AF-upregulated genes
were decreased, and 95 AF-downregulated genes were increased (Figure
3.3.1B).
We performed the principal component analysis (PCA) of the gene expression in
both ileum and liver samples. As shown by PCA plots in Figure 3.3.1, the mice
(PF, AF, and AF+LDNP) partitioned into 3 partially overlapping clusters. The
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centroid location was then calculated for each of 3 cohort groups within the first 3
component spaces (PC1, PC2 and PC3), and the inter-cohort Euclidean distance
of separation was determined. The distance between cluster centroids in the ileal
samples was 203 units for AF versus PF, 127 units for AF versus AF+LDNP and
76 units for PF versus AF+LDNP. The distance between cluster centroids in the
liver was 129 units for AF versus PF, 83 units for AF versus AF+LDNP and 55
units for PF versus AF+LDNP. These spatial distances between the clusters
suggest that tissue gene expression profiles were most similar for PF mice and
AF+LDNP mice, and the most dissimilar for the AF mice versus PF mice. These
findings demonstrated that the alcohol feeding changed ileal and hepatic gene
expression, which was partially restored by LDNP treatment.
The top50 most dysregulated genes in the ileum and liver by alcohol feeding and
LDNP administration were listed in Table 5-8. SULT2A8 is a male-predominant
and liver-specific mouse cytosolic sulfotransferase (SULT) that is uniquely
capable of preferentially catalyzing the sulfonation of 7α-OH group of primary bile
acids, including cholic acid (CA), chenodeoxycholic acid (CDCA), α-muricholic
acid (α-MCA), and their salts or conjugated forms (180). Additionally, male
predominant expression of SULT2A8 (180) corresponds to higher levels of bile
acid sulfates detected in male mice (181). Sulfonation regulates bile acid
homeostasis, which in turn regulates cholesterol and energy metabolism. As
shown in Table 6, liver SULT2A8 level was significantly reduced by alcohol and
restored after LDNP administration. More studies need to be done to validate if
LDNP could attenuate ALD through hepatic SULT2A8-mediated BA sulfonation
pathway.
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Figure 3.3.1. Differential gene expression in ileum and liver of mice treated with
alcohol-feeding (AF) and probiotics LGG-derived nanoparticles (LDNP). Volcano
plots (A1, A2, B1, B2) show genes differentially expressed with at least 2-fold
down (blue) or up (red) at p <0.05. Venn diagrams (A3, A4, B3, B4) show the
amount of overlapping genes between the two treatments in reciprocal direction
(down vs. up, or up vs. down). PCA plots (A5, B5) demonstrated variance within
the groups (ellipsoids with 1x SD) as well as spatial distance between the groups
(calculated with 3-dimentional coordinates of centroids –the small dot within
ellipsoid).
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Table 5

The top50 most down-regulated genes by alcohol feeding and up-

regulated genes by LDNP in the ileum.
Gene_name
Ddx3y
Eif2s3y
Uty
Kdm5d
Gnmt
S100a6
Muc2
Hist1h2bk
G6pc
Agr2
Zg16
Eno1b
Clca1
Fcgbp
Angptl4
Klk1
Fmo5
Nt5e
Hsd3b3
Fbp1
Pmp22
Fabp6
Abcb1a
Serpina1b
Tm4sf4
P2ry4
Hmgcs2
Pck1
Tppp
Cyp2e1
Tst
Gsta1
Pdk4
Ang4
Tff3
Sis
Clca4a
Atoh1
Sult1d1
Kyat1
Cldn4
Lgals3
Cfd
Akr1c19
Naa80
Fabp4
Slc10a5
Rasd2
Sap18b
Fer1l6

AF_vs_PF linear fold change AF_vs_PF_adj.P Value
Gene_name
AF.LDNP_vs_AF linear fold change AF.LDNP_vs_AF_adj.P Value
-50.830726
0.017557878 Ddx3y
35.204707
0.05761368
-48.233301
0.012581222 Eif2s3y
28.655876
0.05428083
-34.191466
0.009337226 Uty
20.308191
0.04815761
-20.198044
0.005503945 Gnmt
17.668425
0.02562534
-19.819169
0.003707908 Kdm5d
11.089352
0.04254411
-18.635442
0.000823093 S100a6
10.428143
0.02108926
-15.538684
0.000338437 Muc2
9.404123
0.02076641
-15.084044
0.007196776 G6pc
8.067394
0.02165361
-13.250296
0.001057108 Zg16
7.743946
0.02076641
-12.779753
0.000314086 Agr2
7.346931
0.02076641
-11.990183
0.000324809 Eno1b
6.577322
0.10214504
-10.206322
0.027660695 Clca1
5.841687
0.02076641
-9.581888
0.000329753 Angptl4
5.554576
0.02076641
-8.884378
0.000461402 Fcgbp
5.491777
0.02076641
-8.850957
0.000356064 Klk1
5.191307
0.04094139
-7.834751
0.005211608 Hsd3b3
5.172083
0.02405577
-7.760722
0.000348977 Fmo5
4.971742
0.02076641
-7.540706
0.000401484 Fabp6
4.95759
0.02076641
-7.4678
0.001670677 Nt5e
4.786442
0.02076641
-7.109838
0.000738223 Hmgcs2
4.691693
0.02076641
-6.958285
0.001232262 Serpina1b
4.577044
0.06415469
-6.627479
0.000759557 Abcb1a
4.504393
0.02207963
-6.569366
0.00104592 Hist1h2bk
4.495335
0.18376452
-6.405763
0.012697621 Pck1
4.424431
0.02591645
-6.314089
0.002507168 Tff3
4.416405
0.02076641
-6.296583
0.001295798 Fbp1
4.328672
0.0220265
-6.270659
0.00031832 Pmp22
4.320097
0.0238858
-6.260498
0.001964356 Sap18b
4.294366
0.13877875
-6.185949
0.001472921 Cyp2e1
4.206815
0.04339924
-6.071298
0.006001162 Agrp
4.174078
0.0936673
-5.873554
0.013360318 Tm4sf4
4.151573
0.02933535
-5.787107
0.006107507 Hist1h4c
4.142497
0.02076641
-5.767225
0.000396118 Tppp
4.067294
0.02523679
-5.726371
0.032422775 Tst
4.019583
0.07674196
-5.702757
0.000395172 Pdk4
4.003403
0.02076641
-5.664298
0.002489262 Gsta1
3.967386
0.04762744
-5.570643
0.004968818 P2ry4
3.914846
0.02519638
-5.488895
0.002659523 Ccdc85b
3.9145
0.07242589
-5.290668
0.001201313 Rasd2
3.908721
0.02076641
-5.268734
0.00124908 Sis
3.878492
0.03171441
-5.259088
0.001143926 2210407C18Rik
3.841508
0.04819119
-5.238073
0.000959337 Clca4a
3.790089
0.04196766
-5.179687
0.00785192 Atoh1
3.659101
0.03361239
-5.164091
0.001857627 G0s2
3.645268
0.11277106
-5.049916
0.002072303 Plek2
3.540643
0.02076641
-5.046655
0.003762001 Lgals3
3.539867
0.02243216
-5.031251
0.000327109 Sult1d1
3.517408
0.02320018
-5.006313
0.000538654 Kyat1
3.465621
0.02562816
-4.995047
0.062641423 Hoxb6
3.457342
0.02076641
-4.851161
0.000338437 Amd2
3.454221
0.10095491

Table 6 The top50 most up-regulated genes by alcohol feeding and downregulated genes by LDNP in the ileum.
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Gene_name AF_vs_PF linear fold change AF_vs_PF_adj.P Value
Gene_name
AF.LDNP_vs_AF linear fold change AF.LDNP_vs_AF_adj.P Value
Gja3
55.31043
0.001300968 Olfr1138
-78.535305
0.02076641
Cldn34b1
54.560164
0.001422034 Khdc1a
-20.527578
0.02563828
Crygs
45.919705
0.002204135 Faiml
-17.138895
0.02207963
Saa1
40.445777
0.012614999 Olfr93
-15.837121
0.02741366
Fmo6
36.382856
0.001890412 Olfr1480
-14.346346
0.04381396
Ankk1
35.889485
0.001191391 4930502E18Rik
-14.105295
0.02368223
Klra6
31.674224
0.006058753 Vmn1r89
-11.139623
0.03314947
Trim75
31.6674
0.002774443 Trim30c
-10.516504
0.02108926
Olfr1396
31.665636
0.010353301 Gm3159
-10.379721
0.04260878
Olfr1340
31.204522
0.001705643 Olfr2
-10.193688
0.02336873
Olfr1458
30.615167
0.003448881 Jsrp1
-10.178223
0.02616907
4932429P05Rik
30.047767
0.001168976 Ccer1
-9.929245
0.026356
Hoxd13
29.076047
0.002979878 Gm1979
-9.850684
0.04191016
Klk1b4
28.090863
0.008643804 Cd300e
-9.797209
0.02556445
Pom121l2
27.98523
0.001626069 Gm5141
-9.672321
0.05273938
Duxbl1
27.66028
0.003862513 Tcte1
-9.34096
0.026356
Vmn2r17
27.212517
0.00404179 1810009A15Rik
-9.172175
0.05273938
Gm15155
26.947121
0.005323086 Olfr119
-9.044878
0.05410565
Gm5771
26.03017
0.001919185 Prr19
-8.992715
0.03102856
Pbsn
25.734881
0.002609397 Timd2
-8.926526
0.02165361
Serpinb3b
25.172075
0.00660688 Crygs
-8.81073
0.06091463
Prr9
24.427124
0.004642218 Rgs18
-8.802392
0.0330777
Spin2f
24.412865
0.005242433 Cryba2
-8.616635
0.02076641
Ces1b
24.150423
0.001348615 Tal2
-8.54924
0.03412862
4930502E18Rik
23.936143
0.001014302 Vmn2r103
-8.537258
0.02583061
Skint11
23.849432
0.005297988 Prl2c2
-8.452281
0.06451548
Plscr5
22.96201
0.003778379 2310057J18Rik
-8.344371
0.03745935
AU015836
22.881934
0.004270771 Asb9
-8.279501
0.04385451
Fbxw20
22.627934
0.000751851 Gm15155
-8.187676
0.05473232
Cyp1a2
22.382971
0.010004758 Mrgprb1
-8.171232
0.02648128
BC048671
22.3413
0.014749721 Klk1b27
-7.950646
0.04068652
Cldn34b2
22.236638
0.009704847 Fbxw22
-7.876374
0.02700435
Mc4r
22.172184
0.002382169 Vmn2r15
-7.811747
0.09648048
Dhrs2
22.137528
0.003244318 4930550L24Rik
-7.752375
0.05677286
Cd40lg
22.121898
0.001850384 Slc22a7
-7.736886
0.04043753
Vmn2r106
22.103974
0.003032632 Ntf5
-7.676772
0.03694117
Gm1979
21.633818
0.003633492 Fam122c
-7.605977
0.04392839
Sult1c1
21.455653
0.013896256 Ctsq
-7.511483
0.02857825
Klk7
21.3769
0.000613026 Cldn34b2
-7.436005
0.0732969
Prl2c2
21.349459
0.008418739 Gp6
-7.427289
0.03753081
Gm648
21.236643
0.002019925 Spata4
-7.380896
0.0366976
Slc45a2
21.014597
0.00218165 Sfrp4
-7.345522
0.0246947
Msx2
20.779861
0.000697778 Slc22a27
-7.344848
0.02267824
Cela2a
20.606993
0.003125272 Sult1c1
-7.267495
0.08301794
Vmn2r53
20.569067
0.004283185 Gm10376
-7.210525
0.08864676
Vmn2r82
20.221804
0.007911413 Olfr121
-7.191065
0.02945196
Adam29
20.200811
0.008887669 Idi2
-7.178738
0.02259076
Olfr287
20.178578
0.002100433 4921524L21Rik
-7.15203
0.03872142
Vmn1r89
19.924629
0.002446123 Esx1
-7.106462
0.07398536
Fshr
19.892599
0.000831396 Gm7347
-7.044544
0.03325275

Table 7 The top50 most down-regulated genes by alcohol feeding and upregulated genes by LDNP in the liver.
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Gene_name
Cyp4a12b
Saa1
Cyp4a12a
Nat8f5
Scara5
Eif2s3y
Sprr1a
Saa2
Art2b
Aqp4
Ms4a4c
Cxcl13
Ifi202b
Ces3b
Gpnmb
Acot1
Mup11
Sult2a8
Lcn2
Cidec
Mup7
Apoa4
S100a8
Inhbe
Sftpa1
Reg3b
Lad1
Fmo3
Hist1h4k
Fabp2
Cyp4a31
B3galt1
Nnmt
Spata46
D130040H23Rik
Sult1e1
Retnlg
Cyp4a10
Mettl24
Saa3
Ccr1
Pkdrej
Ccn2
Ttll8
Kdm5d
Zfp599
Slc10a2
Mmp8
Olfr1033
Gm17662

AF_vs_PF linear fold change AF_vs_PF_adj.P Value Gene_name
-47.643
0.006677249
Sprr1a
-31.6349
0.02325634
Saa1
-28.8086
0.000571736
Cyp4a12b
-26.6264
0.0540731
Cyp4a12a
-19.2416
0.001786526
Scara5
-18.4272
0.1799227
Eif2s3y
-16.6273
0.2746964
Saa2
-15.0803
0.06507551
Ifi202b
-13.7768
0.05947473
Ms4a4c
-12.603
0.001188493
Nat8f5
-11.2586
0.03084892
Art2b
-10.2563
0.03212771
Aqp4
-10.1829
0.02616794
Sult1e1
-8.32887
7.01E-06
Gpnmb
-8.26747
0.2083464
Lcn2
-8.24177
0.001069326
Hist1h4k
-7.8163
0.02241531
Fmo3
-7.75508
0.00394965
Retnlg
-7.62992
0.00121512
Nnmt
-7.60569
0.00193509
Ces3b
-7.32506
0.04709053
Clec4a2
-7.25047
0.008021074
Acot1
-6.87594
0.02976715
D130040H23Rik
-6.78802
0.00395386
Cxcl13
-6.65448
0.007522028
Cidec
-6.64071
0.1345341
Apoa4
-6.4521
0.005481361
Sftpa1
-6.41282
0.09721753
Sebox
-6.17766
0.1681202
Defb1
-6.00085
0.000525537
P2ry10b
-5.94884
4.06E-05
Eno1b
-5.84799
0.000132672
Cyp4a31
-5.76869
0.008441311
B3galt1
-5.76805
0.104954
Ubd
-5.63098
0.1817125
Sult2a8
-5.5736
0.1121911
Insyn1
-5.35555
0.07478228
Chil1
-5.19082
0.000156686
Mup11
-5.08866
0.2264321
Mmp8
-5.07804
0.008152612
4933408B17Rik
-4.98327
0.03818635
Lad1
-4.93396
0.04379864
Spata46
-4.83061
0.004259105
Mup7
-4.77529
0.002480105
Fam107a
-4.65131
0.2266819
Kdm5d
-4.57706
0.007361565
Fam83a
-4.54344
0.003119919
Cyp4a10
-4.4273
0.006206661
E030018B13Rik
-4.35543
0.005513371
Ccn2
-4.34216
0.1459143
Inhbe

AF.LDNP_vs_AF linear fold change AF.LDNP_vs_AF_adj.P Value
41.38434
0.17839
30.1126
0.042307
26.88809
0.029928
20.92443
0.003512
16.32816
0.006053
15.84025
0.263044
14.09205
0.106209
11.43957
0.03612
10.93584
0.058177
10.17845
0.221194
9.819246
0.151231
9.320892
0.005857
8.639005
0.074269
8.616944
0.267413
7.746556
0.004862
7.492213
0.169029
7.183385
0.124973
7.104587
0.06073
6.855518
0.0143
6.77908
9.20E-05
6.686406
0.031314
6.656755
0.006422
6.514631
0.195284
6.160903
0.129081
6.121246
0.011477
6.056151
0.042653
6.02787
0.022024
5.902551
0.066283
5.874403
0.08603
5.835121
0.162758
5.664519
0.356146
5.66045
0.000172
5.513098
0.00068
5.490413
0.513477
5.459654
0.031896
5.345267
0.107457
5.29691
0.104813
5.246628
0.097984
5.237959
0.007232
5.072677
0.065275
5.012334
0.027319
4.83275
0.188622
4.664585
0.172727
4.597501
0.216212
4.549029
0.310964
4.53849
0.089173
4.470016
0.001866
4.366084
0.003404
4.33896
0.01645
4.30081
0.042104

Table 8 The top50 most up-regulated genes by alcohol feeding and downregulated genes by LDNP in the liver.

86

Gene_name
Gm10715
Adgrb3
Dnah7a
Kif6
Sytl5
Gm10721
Hmmr
Cdh10
AW551984
Hist1h2ah
Gdap1
Fbxo43
Ndst4
Ros1
Fer1l4
Brinp3
Col28a1
Col6a5
Cdh7
Slc24a2
Gm5415
Dnah11
Elavl4
Slc26a9
Spta1
Scn1a
Khdrbs2
Cdc25c
Zic4
Gpr158
Six1
Prkg2
AC168977.1
Ak9
Cntnap5a
Scn3b
Cyp2g1
Muc5ac
Gm10800
Tdrd9
Gm10717
Gm21738
Pld5
Dnah7c
Cemip
Cdc6
Dlx1
Mylk4
Pfn4
Usp13

AF_vs_PF linear fold change AF_vs_PF_adj.P Value Gene_name
173.8398
0.01301781
Gm17535
113.8365
0.00082488
Abca13
99.49466
0.001294139
Hist1h2ag
77.7754
0.001194479
Spta1
73.75992
0.01144715
Fsip2
68.28525
0.006206661
Gm11168
64.32434
0.001294139
Gm10722
62.31752
0.001294139
Ak9
60.65836
0.00193509
Lrp1b
58.38965
0.0162428
Abca12
55.6138
0.001634923
Opcml
55.38136
0.001540811
Nptx1
52.6287
0.000940361
Gm10720
52.53758
0.004140043
Trpm1
52.20476
0.006504516
Gm10718
52.16063
0.002480067
Gm10717
50.72408
0.002564544
Grid2
49.91952
0.004269127
Muc5ac
48.96472
0.006215419
Cntnap5a
48.92068
0.001634923
Dcc
48.82897
0.003686695
Cdh10
48.63265
0.005286483
Gm10719
47.48448
0.002232339
Scn1a
46.33699
0.00608865
Elavl4
44.64898
0.006206661
Gm10721
44.00002
0.006033469
Gdap1
43.92328
0.002234305
Myo3b
43.30827
0.01054777
Dgki
42.55431
0.001634923
Gm10800
42.17622
0.002183363
Fbxo43
42.11604
0.002307044
Khdrbs2
41.84217
0.006033469
Cadps
41.63655
0.003716287
Sorcs1
40.86697
0.007261634
Npas3
40.11124
0.002679045
Kcnb2
39.9641
0.005497653
Chl1
39.18463
0.02928961
Sorcs3
38.68749
0.004001475
AF366264
38.47006
0.02326279
Gm5415
38.39665
0.002655359
Kif6
38.36063
0.009383237
Cdh20
38.2593
0.008646599
Otogl
38.09425
0.003234602
Col28a1
38.00078
0.006828348
Unc80
37.5366
0.003761758
Sphkap
37.22383
0.005964815
Pou6f2
37.0982
0.00288181
Dnah7a
36.74265
0.003745755
Gm21738
36.34345
0.02440256
Csrnp3
35.47103
0.002554849
Kel

AF.LDNP_vs_AF linear fold change AF.LDNP_vs_AF_adj.P Value
-135.717
0.070368
-100.925
0.017649
-92.5766
0.072471
-87.6072
0.016303
-86.4208
0.006121
-73.953
0.049076
-71.9305
0.024594
-71.7943
0.020644
-70.1744
0.008056
-68.9009
0.014298
-68.2001
0.023608
-67.426
0.023933
-65.5096
0.121939
-58.8998
0.013889
-58.8463
0.040954
-58.765
0.024477
-58.2452
0.058036
-58.0186
0.013889
-57.2697
0.010486
-56.6644
0.022885
-55.4086
0.009065
-55.3263
0.046054
-54.9462
0.024594
-54.705
0.011187
-51.1278
0.04017
-51.0377
0.011176
-50.9136
0.018553
-50.8835
0.033166
-50.6368
0.042307
-50.6253
0.010041
-49.1568
0.011578
-48.6531
0.02116
-48.3101
0.029203
-48.3092
0.024208
-46.9218
0.045573
-46.8307
0.02831
-46.5774
0.029264
-46.437
0.029182
-46.0512
0.022885
-45.9015
0.013889
-45.36
0.022275
-44.7773
0.040954
-44.6844
0.017649
-44.4084
0.030395
-43.9578
0.027721
-43.5871
0.039207
-42.9539
0.021781
-41.3837
0.024594
-41.2566
0.022494
-40.9495
0.026764

3.3.2 Analysis of Gene Function by GO Term Enrichment
The Metascape enrichment analysis in the ileal genes showed that many of GO
terms enriched in AF-upregulated or downregulated genes were seen in the GO
terms enriched in LDNP-downregulated or upregulated genes (Fig. 3.3.2A).
Similarly, GO terms enriched in the liver genes followed a same overlapping
pattern between AF- and LDNP-regulated genes (Fig. 3.3.2B).
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A

B

Figure 3.3.2. Gene Set Enrichment Analysis revealed dysregulated pathways in
RNA-seq. (A) Pathway enrichment in ileum genes. (B) Pathway enrichment in
liver genes. The x-axis represents the -log10 P-values. Upregulated genes are
indicated by red and the downregulated by blue.
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Considering such a special scenario, comparative GO term enrichment was
performed across pairs of gene lists in both ileum and liver datasets. Figure
3.3.3A and 3.3.4A (upper panel) include AF-downregulated genes and LDNPupregulated genes. While Figure 3.3.3A and 3.3.4A (lower panel) constitute
genes upregulated by AF and downregulated by LDNP.
As shown in Figure 3.3.2A upper panel, the cilium movement, cell-cell adhesion
via plasma-membrane adhesion molecules, detection of abiotic stimulus, and
organic anion transport were increased by alcohol and decreased after LDNP
administration. Additionally, monocarboxylic acid metabolic process, sulfur
compound metabolic process, lipid biosynthetic process, and response to
oxidative stress (Figure 3.3.2A, lower panel), which was decreased by alcohol
and restored after LDNP treatment. Figure 3.3.3C shows that heatmap of genes
in selected GO. It is clearly that the genes in GO terms, monocarboxylic acid
metabolic process, sulfur compound metabolic process, lipid biosynthetic
process, and response to oxidative stress, were down-regulated by alcohol
exposure and restored by LDNP treatment (Fig 3.3.3B(1-4)). The genes in GO
terms, cell-cell adhesion via plasma-membrane adhesion molecules, cilium
movement, detection of abiotic stimulus, and organic anion transport, showed the
opposite effect and were up-regulated by alcohol and suppressed by LDNP
treatment (Fig 3.3.3B(5-8)).
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Figure 3.3.3 Biological process enrichment in ileum genes. (A) Comparative
enrichment of gene lists (outer colored circular bars) constituted with reciprocally
regulated genes in AF vs. PF and AF+LDNP vs. AF contrasts. The inner circular
bars show the overlap of genes and enriched gene ontology (GO) terms. The
purple lines in the circle connect the same genes in the two gene lists and the
blue lines connect the genes with identical GO terms between the two gene lists.
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(B). B(1)-B(4) are for GO terms enriched with Pair1 genes that were upregulated
by LDNP in AF mice and downregulated by AF over PF treatment; and C(5)-C(8)
are for those GO terms enriched with Pair2 genes that were regulated oppositely
to genes in Pair1, i.e., downregulated by LDNP in AF mice and upregulated by
AF over PF treatment.
The top upregulated GO terms by alcohol in the liver genes were response to
xenobiotic stimulus, glutathione metabolic process, extracellular matrix
organization, and sterol biosynthetic process in (Figure 3.3.2B, upper panel), and
monocarboxylic acid metabolic process, acute-phase response, regulation of
triglyceride metabolic process, and those responsive to reactive oxygen species
were the most decreased terms by alcohol (Figure 3.3.2B, lower panel). Similar
to the results of liver sample, the monocarboxylic acid metabolic process is also
reduced by alcohol and increased after LDNP treatment in ileum. Importantly,
extracellular matrix organization is a process that is carried out at the cellular
level and results in the assembly, arrangement of constituent parts, or
disassembly of an extracellular matrix. The fibrotic stage of ALD is primarily
characterized by robust accumulation of extracellular matrix (ECM) proteins
(collagens) which ultimately impairs the function of the organ (182). Our data
would suggest that LDNP reduce alcohol-induced extracellular matrix
accumulation and protect from ALD, but future investigation is required to
validate this concept. Previously, it has been shown that disorders of fatty acid
oxidation, such as peroxisome defects, and inherited abnormalities in the
enzymes of acyl-CoA oxidation lead to the development of fatty liver, and one of
the original mechanisms for alcoholic steatosis was the inhibition of β-oxidation
caused by accumulation of NADH and product inhibition of the mitochondrial fatty
acid-oxidizing dehydrogenases (183), consistent with the findings of this study.
Enriched genes in these GO terms were further examined by expression heat
maps (Figure 3.3.3B).
Taken together, these data demonstrate that LDNP are anti-fibrotic and
beneficial in the liver during ALD.
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Figure 3.3.4 Biological process enrichment in liver genes. (A) Comparative
enrichment of gene lists (outer colored circular bars) constituted with reciprocally
regulated genes in AF vs. PF and AF+LDNP vs. AF contrasts. The inner circular
bars show the overlap of genes and enriched gene ontology (GO) terms. The
purple lines in the circle connect the same genes in the two gene lists and the
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blue lines connect the genes with identical GO terms between the two gene lists.
(B) B(1)-B(4) are for GO terms enriched withPair1 genes that were upregulated
by LDNP in AF mice and downregulated by AF over PF treatment; and B(5)-B(8)
are for those GO terms enriched with Pair2 genes that were regulated oppositely
to genes in Pair1, i.e., downregulated by LDNP in AF mice and upregulated by
AF over PF treatment.
3.3.3 Functional Analysis of Differentially Expressed Genes.
The MCODE analysis within the Metascape helped identify significant underlying
biological functions in the protein-protein interaction networks (Figure 3.3.6A,
3.3.7A and 3.3.7C) formed with genes in gene lists for GO term enrichment. For
genes in network A in the ileum, 7 MCODE clusters were identified that were
upregulated by LDNP treatment in alcohol-fed mice (Figure 3.3.6B). These
MCODE clusters were significantly enriched to certain GO terms, 3 of which with
the best score by p-value are shown in Figure 3.3.6B.

Figure 3.3.6. Protein interaction network formed among genes up-regulated by
LDNP intheileum of AF mice. (A) Network with full connectionsidentified in
STRING (physical score > 0.132) and BioGriddatabases. (B) Densely connected
network componentsidentified by the Molecular Complex Detection (MCODE)
algorithm. Shown are select MCODE complexes more relevant to the study, each
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annotated with the three best-scoring GO terms by p-value (numbers after | sign
are log10 of p-value).

Figure 3.3.7 Protein interaction network formed among genes down-regulated by
LDNP and up-regulated by AFin the liver of studymice. (A) and (C) Network with
full connections identified in STRING (physical score > 0.132) and
BioGriddatabases. (B) and (D)Densely connected network componentsidentified
by the Molecular Complex Detection (MCODE) algorithm. Shown are select
MCODE complexes more relevant to the study, each annotated with the three
best-scoring GO terms by p-value (numbers after | sign are log10 of p-value).
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In the ileum, no protein to protein interaction (PPI) network was formed by genes
that was downregulated by AF over PF. In addition, no PPI network but a few
MCODE clusters in the ileum was found in genes upregulated by AF over PF or
downregulated by LDNP in AF mice (Figure 3.3.8A-B). In the liver, genes
downregulated by AF over PF and genes upregulated by LDNP in AF mice did
not form substantial PPI networks, but a few MCODE cluster were found in these
genes (Figure 3.3.8C-D). In the liver genes that were upregulated by AF over PF
and those downregulated by LDNP in AF mice, substantial PPI networks were
observed (Figure 3.3.7A-C). Among these networks, several MCODE clusters
were identified, of which the most relevant ones to the current study were shown,
with top 3 enriched GO terms listed along to further interpret the biological
functions of these MCODE clusters (Figure 3.3.7B-D).
As shown in Figure 3.3.6B, those significant ileum MCODE clusters were
enriched with specific GO terms, including fatty acid catabolic process, fatty acid
beta-oxidation, glutathione metabolic process, integrin-mediated signaling
pathway, proton transmembrane transport, bi-cellular tight junction assembly,
and secondary alcohol biosynthetic process. These results indicate that LDNP
treatment increased fatty acid oxidation that favors ileum fat degradation, an
upregulation of ileum energy supply, and an improvement of intestinal barrier
function in alcohol-fed mice. In addition, AF-upregulated ileum genes enriched 2
MCODE clusters, with top GO terms of fucosylation and positive regulation of
lactation; meanwhile LDNP-downregulated ileum genes enriched one MCODE
cluster annotated with ceramide metabolic process and sphingolipid metabolic
process (Figure 3.3.8A-B).
The liver MCODE clusters identified in AF-downregulated and LDNP-upregulated
genes both centered on GO terms of lauric acid metabolic process and acutephase response (Figure 3.3.8C-D). On the other hand, AF-upregulated and
LDNP-downregulated liver genes, encompassed a group of MCODE clusters that
were overlapped each other, such as xenobiotic metabolic process, drug
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metabolic process, extracellular matrix organization, and ATP synthesis coupled
electron transport, with a few selective MCODE clusters for LDNP-downregulated
genes, which were annotated with purine ribonucleotide biosynthetic process,
cholesterol biosynthetic process, and cardiac muscle fiber development (Figure
3.3.7B & 7D).
Compared to the upregulated MCODEs, we identified only one MCODE that was
downregulated by LDNP treatment, and that was associated with ceramide
metabolism, sphingolipid metabolism and membrane lipid metabolism and
included Galc, Cers3, and Ugt8a. Two MCODEs were upregulated by alcohol
feeding, and were associated with fucosylation and protein glycosylation, and
regulation of lactation. The genes included Sec1m Fut1, Fut2, Fut9, and B3galt5,
and Pri3c1, Prl2c2, Prl2c3 and Prl3a1, respectively (Figure 3.3.6B).
In the liver, 3 clusters were identified that were downregulated by alcohol
feeding, of which 2 of them were upregulated by LDNP treatment. These were
associated with medium-chain-fatty acid metabolism and acute inflammatory
response. In the medium-chain fatty acid metabolism MCODE, genes include
Cyp4a1, Cyp4a2 and Cyp4a3, while in the inflammatory response MCODE, there
were Saa3, Apoc2, Saa1, Saa4 and Apoa4. One MCODE that was exclusively
down-regulated by alcohol was associated with thioester metabolism, acyl-CoA
metabolism and purine nuclearside bisphosphate metabolism and included
genes Fgg and Fgb (Figure 3.3.7A).
We identified 5 clusters of genes that were upregulated by alcohol feeding, all of
which were all downregulated by LDNP treatment (Figure 3.3.7B). MCODE 1
was associated with xenobiotic metabolism, including genes Gstp2 and Slc22a4.
MCODE2 was also associated with xenobiotic metabolism, which included genes
Ugt2b35, Gabp-1 and Glyats. The third MCODE included gene ND2, which was
associated with ATP energy metabolism. MCODE 4 included Adamts9, which
was associated with extracellular matrix organization. MCODE 5 was also
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associated extracellular metabolism, and included genes Col24a1, MMP-2 and
MMP-3.

Figure 3.3.8. Altered MCODE by AF over PF in the ileum (A and B) and liver (C
and D) of study mice.

3.4 Discussion
Although the studies on pathological mechanisms of ALD have been advanced in
recent years, the detrimental effects of alcohol exposure on intestinal and liver
tissue integrity and function remains incompletely understood (184, 185).
Moreover, there are still no effective treatment for any stages of ALD.
Understanding the precise mechanisms of ALD pathology will promote the
development of effective strategy for the management of ALD.
Probiotics have been shown to improve alcohol-induced gut leakiness and
endotoxemia and liver injury in animal models. Our previous studies have
demonstrated that probiotic LGG-derived exosome-like nanoparticles (LDNPs)
protected against ALD by modulation of intestinal AhR and FXR mediated
signaling pathways, which increased antimicrobial activity leading to inhibition of
gut leakiness, FGF15 secretion leading to the suppression of de novo BA
synthesis and lipogenesis in the liver, respectively. However, additional signaling
pathways need to be explored to help better design the treatment regimes using
probiotic-derived products.
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In the present study, liver and ileum tissues from mice treated with alcohol and
LDNP were analyzed to identify differentially expressed genes (DEGs) that may
be critical to explain the pathological effects of alcohol exposure and the
protective effects of LDNPs. This transcriptomic profiling revealed unique DEGs
and gene functions in the ileum and liver of mice treated with binge-on-chronic
alcohol feeding and LDNPs. Compared with PF group, alcohol feeding
significantly altered a large set of genes in the ileum and liver. Importantly, many
of the altered DEGs by alcohol exposure were oppositely regulated by LDNP
treatment. According to GO categories and Reactome Gene Sets, differentially
expressed proteins were primarily involved in monocarboxylic acid metabolic
process, sulfur compound metabolic process, lipid biosynthetic process, and
response to oxidative stress in ileum and monocarboxylic acid metabolic
process, acute-phase response, regulation of triglyceride metabolic process, and
response to reactive oxygen species in liver. Similarly, LDNP treatment group
improved these effects on the gene function that were changed by alcohol
exposure. These results indicate that the potential deleterious effects on hepatic
and intestinal gene expression and function by alcohol exposure can be inhibited
by LDNP treatment.
In addition, confirming our previous findings, the identified DEGs provide an
important resource for further explore the action of alcohol and LDNPs in ALD.
For example, in the ileal tissues, alcohol feeding markedly decreased Ddx3y,
Eif2s3y and Uty gene expression by 50-, 48-, and 34-folds, respectively, which
were completely restored by LDNP treatment completely (Table 5). Interestingly,
these genes are involved in the cell proliferation (186-188) , suggesting alcohol
may negatively affect the intestinal cellular renewal, and LDNP treatment may
play a role in intestinal cell proliferation that leads to enhanced barrier integrity in
ALD. In addition, these genes are male-specific, showing that the function of
these genes may help understand the sex dimorphism (189) in ALD. Previous
studies demonstrated that ALD exhibits a sex-dimorphism feature and defected
intestinal cellular proliferation. However, these issues need further study.
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The interatomic analysis provides further insight into the regulatory cross-talk.
The upregulated MCODE members including Sac1, Fut2, Fut9, Fut1, and
B3galt5 are involved in protein modifications, such as fucosylation and
glycosylation. While dysregulated protein glycosylation has been considered as a
contributory factor for the alcohol-induced liver injury (190-192), and recent study
also showed that protein fucosylation was involved in alcohol induced barrier
dysfunction (193). The functions of these new identified genes in protein
glycosylation and fucosylation in the ileum of subjects exposed to alcohol need
further investigation.
In conclusion, those transcriptomic findings provide additional information on how
alcohol affects intestinal and hepatic homeostasis and how LDNP treatment
protects from alcohol-induced tissues injury. The identified DEGs need further
validation in mRNA and protein levels in animals and humans with ALD.
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ABBREVIATIONS

ALP
alkaline phosphatase
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BA
bile acid
BSEPia
bile salt export pump
BSH
bile salt hydrolase
C4
7-alpha-hydroxy-4-cholesten-3-one
CDCA
chenodeoxycholic acid
CFU
colony-forming units
CYP7A1
cholesterol 7α-hydroxylase
CYP8B1
sterol 12α-hydroxylase
CYP7B1
oxysterol 7α-hydroxylase
CYP27A1
sterol 27-hydroxylase
FGF
fibroblast growth factor
FXR
farnesoid X receptor
IL-6
interleukin-6
LCA
lithocholic acid
LGG
Lactobacillus rhamnosus GG
α/β-MCA
α-/β-muricholic acids
Mdr2
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multidrug resistance protein 2
MRP
multidrug resistance–associated protein
OST-α/-β
organic solute transporter subunits alpha/beta
SHP
small heterodimer partner
α-SMA
alpha-smooth muscle actin
T-α-/T-β-MCA
taurine-α-/β-MCAs
TNF-α
 tumor necrosis factor alpha
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